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ABSTRACT 
 
EFFECTS OF HYDROGEN SULFIDE IN HYPERHOMOCYSTEINEMIA-MEDIATED 




November 20th, 2018 
 
Although hyperhomocysteinemia (HHcy) occurs due to a deficiency in 
cystathionine-β-synthase (CBS), causing skeletal muscle myopathy, it is still unclear 
whether this effect is mediated through oxidative, endoplasmic reticulum (ER) stress, 
both or something else. Cystathionine γ-lyase (CSE) and CBS are the main H2S 
producing enzymes, which produce Hydrogen sulfide (H2S) from Hcy in the 
transsulfuration reaction. H2S is an anti-oxidant compound and patients with a CBS 
deficiency cannot produce enough H2S, thus rendering them vulnerable to excess Hcy-
mediated damage.  
Both in-vitro (C2C12 cells) and in-vivo (CBS+/- mice) models were used to study 
HHcy-mediated muscle myopathy, and they were treated with sodium hydrogen sulfide 
(NaHS, an H2S donor) to mitigate the effect(s) of HHcy in skeletal muscle. To examine 
whether muscle myopathy is due to poor angiogenesis, we created a hind limb femoral 
artery ligation (FAL) in CBS+/- mouse model and treated them with GYY4137 (a long-
acting H2S donor compound).
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Results showed that oxidative stress was reversed by NaHS (H2S donor) in Hcy-
treated C2C12 cells. ER stress markers (GRP78, ATF6, and pIRE1α) were elevated both 
in-vivo and in-vitro, and NaHS mitigated these effects. JNK-phosphorylation was 
upregulated in C2C12 cells after Hcy treatment, but NaHS could not reduce this effect. 
Apoptosis was induced after Hcy treatment, and it was mitigated by the NaHS 
supplementation in C2C12 cells.  
HIF1-α, VEGF, PPAR-γ and p-eNOS expression levels were attenuated in 
skeletal muscle of CBS+/- mice after 21 days of FAL in comparison to WT mice and 
were improved via the GYY4137 (another H2S donor compound) treatment. Collateral 
vessel density and blood flow were significantly reduced in post-FAL CBS+/- mice 
compared to WT mice, and these effects were ameliorated by the GYY4137 treatment. 
Plasma nitrite levels were decreased in post-FAL CBS+/- mice compared to WT mice, 
and these were improved by GYY4137 supplementation.  
I also noticed FOXO1-mediated MuRF-1 upregulation, which further degrades 
MHC-I in CBS+/- mice compared to WT mice, and these effects were improved by NaHS 
intervention. Functional studies revealed that NaHS administration improved muscle 
fatigability in CBS+/- mice. 
This work provides evidence that H2S is beneficial in mitigating HHcy-mediated 
skeletal muscle injury incited by oxidative or ER stress responses and H2S might be 
employed as a potential therapeutic to alleviate the harmful metabolic effects of HHcy 
conditions.
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CHAPTER I  
OVERVIEW (1) 
 
Homocysteine (Hcy) has been studied extensively for over 30 years for its unique 
involvement in an increasing number of human diseases (2-4). It is generated via 
methionine cycle (MET-cycle) and its level is controlled by two processes: around 50% 
of Hcy goes to the transsulfuration pathway to produce cysteine, and the other half is re-
methylated back to methionine (MET) via the folate cycle (5-7) (Fig. 1). The normal total 
plasma Hcy concentration in the body is 5-15 μM, however, in a diseased condition, i.e., 
hyperhomocysteinemia (HHcy), total plasma Hcy levels increase (>15 μM) (8). HHcy can 
be classified as moderate (15-30 μM), intermediate (30–100 μM) and severe (>100 μM) 
(7,8). There are mainly 4 ways humans can develop HHcy: (1) methionine-rich protein 
diet (9); (2) Vitamin B12/folate deficiency (10); (3) heterozygous/homozygous for 
cystathionine-β synthase (11); and (4) obstruction of renal clearance (12).   
 
          2 
Figure 1: Schematic representation of Hcy metabolism. (A) Dietary methionine is 
converted to homocysteine (Hcy) through S-adenosyl methionine (SAM) and S-adenosyl 
homocysteine (SAH) and then back to methionine (MET).  Hcy also bifurcates to the 
transsulfuration pathway where it is converted to cysteine in presence of rate-limiting 
enzymes cystathionine-β synthase (CBS) and cystathionine-γ lyase (CSE). Cysteine 
generated through transsulfuration pathway is further converted to glutathione (GSH); 
(B) Conversion of cobalamin (Vitamin B12) to methyl-B12 in the presence of methionine 
synthase reductase (MTR) is necessary for remethylation of 5-methyl- tetrahydrofolate 
(THF) to THF; (C) Dietary folic acid (Vitamin B9) enters the folate cycle after its 
conversion first to dihydrofolate (DHF) and then to THF. The 5, 10-
methyltetrahydrofolate reductase (MTHFR) is a key enzyme that converts 5, 10-
methylene-THF to 5-methyl-THF.  
 
HHcy has been associated with severe skeletal muscle dysfunction, but the precise 
mechanism(s) is still unknown (7,13-20). Children born with very high levels of Hcy, i.e., 
HHcy caused by a lack of functional CBS alleles, show severe dysfunction of the 
musculoskeletal system and die shortly after birth, but individuals that heterozygous for 
non-functional CBS mutations can survive (13). Previous studies reported that HHcy 
could cause disruption of Z-discs, fiber size, and excessive collagen deposition in 
muscle (15,20,21), but the pathways that trigger such pathological effects in skeletal 
muscles are not fully understood. Loss of skeletal muscle mass (muscle wasting) is 
mediated mainly by three processes: apoptosis, poor vasculature, and atrophy (protein 
degradation exceeds protein synthesis over time) (22,23). Therefore, identification of 
the precise molecular mechanism(s) regulating the processes underlying HHcy is 
essential to devise proper treatment strategies. Findings from our group and other 
groups determined that HHcy induces oxidative stress in endothelial cells (24), vascular 
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smooth muscle cells (25), liver tissue (26), and brain (27). Oxidative stress has been 
implicated in many diseases associated with protein misfolding and reduction of 
efficiency of protein folding pathways (28-33), but the cellular pathways that are involved 
in these stress-related conditions have not been elucidated. During severe ER-stress 
conditions, activated IRE1 recruits’ TNF receptor-associated factor 2 (TRAF2) and 
apoptosis signal-regulating kinase 1 (ASK-1), which further activates c-Jun N-terminal 
kinase (JNK) (34-36) (Fig. 2). However, whether HHcy can compromise cell survival via 
activation of JNK is not studied previously. AKT is a major survival factor promoting cell 
proliferation, and its dysregulation has been detected in muscle wasting (37-39). A 
previous study showed that activated JNK could induce inhibitory phosphorylation of 
IRS-1 at Ser307 (40). Since Ser307 phosphorylation promotes general inhibition of IRS-1 
signaling, it suggests that JNK-activation may impair PI3K/Akt axis (41). JNK controls 
cell response to the harmful extracellular stimulus (42,43). JNK/c-Jun pathway regulates 
pro-apoptotic and pro-inflammatory gene expressions (44). Whether HHcy mediates 
oxidative and ER-stress responses, and whether this further induces apoptosis in 
muscle, has not been studied previously. 
 
Figure 2: A schematic highlighting hyperhomocysteinemia mediated skeletal muscle 
dysfunction. HHcy can induce cell death via induction of ER and oxidative stress 
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responses that can lead to skeletal muscle cell death via JNK-activation and concurrent 
impairment of PI3K/AKT survival axis. 
HHcy is implicated in vascular toxicity, causing endothelial cell damage and 
dysfunction (20,45-47). Although several markers of ER-stress, including CCAAT-
enhancer-binding protein homologous protein (CHOP), have been shown to be 
increased in a model of skeletal muscle atrophy, whether HHcy mediated ER-stress can 
play a role in muscle atrophy is still unclear (48). Additionally, several models of atrophy 
showed that inhibition of PI3K/Akt signaling induces nuclear import of FOXO in 
regulating Atrogin-1 and MurF-1 expression (49,50). Some studies have already 
demonstrated that HHcy inhibits Akt activation in endothelial cells (47), but whether this 
similar mechanism can be attributed to muscle myopathy is yet to be explored (37).  
H2S is increasingly being recognized as an important signaling molecule in the 
cardiovascular and nervous systems via its ability to neutralize a variety of reactive 
oxygen species (ROS) (51-53), as well as via increased cellular glutathione (GSH) levels 
through activation/expression of -glutamylcysteine synthetase (54-61). Cystathionine γ-
lyase (CSE) and CBS are the main H2S producing enzymes, which produce H2S from 
Hcy in the transsulfuration reaction (62). CBS gene mutation leads to dysfunction in 
endogenous H2S biosynthesis (63), suggesting that patients with this mutation are more 
prone to oxidative stress-mediated damages due to malfunction in Hcy metabolism and 
inefficient H2S biosynthesis (54). CBS is a crucial enzyme in the transsulfuration 
pathway, and heterozygous CBS deficient (CBS+/-) mice show mild to severe 
endogenous elevation of circulatory Hcy levels (64-71) and lower levels of H2S in their 
blood, which lead to oxidative stress-mediated damage (72,73). Hence, it is important to 
study the mechanism of exogenous supplementation of H2S as a possible approach to 
mitigate the effects of HHcy condition in skeletal muscle myopathy.  
In this study, I examine the potential mechanisms of HHcy-mediated oxidative 
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stress, ER stress, inflammation, apoptosis, angiogenesis, and atrophy in skeletal 
muscle, and whether H2S has any beneficial role on mitigating these effects.  
 
1. Homocysteine and Hyperhomocysteinemia 
Homocysteine (Hcy) is a sulfur-containing non-proteinogenic amino acid that is 
produced during the metabolism of methionine (MET) via MET-cycle (2). Post 
absorption, MET is converted into S-adenosylmethionine (SAM) by ATP and catalyzed 
by methionine adenosyltransferase (MAT), leaving it with a transferrable methyl group. 
This methyl group is donated for cellular methylation requirements and becomes S-
adenosyl-homocysteine (SAH). SAH hydrolase is an enzyme that reversibly hydrolyzes 
SAH and produces Hcy (74). Hcy is present in blood in three different forms: around 1% 
as free thiol, 70–80% as a disulfide-bound to a swath of plasma proteins, and the 
remaining 20-30% as a homo/heterodimerize with other thiols (3). Upon the generation 
of Hcy via the MET-cycle, 50% goes to the transsulfuration pathway for production of 
glutathione (GSH, an antioxidant) and the rest is re-methylated back to MET via the 
folate cycle as shown in Fig. 1 (2,5,6).  
In healthy individuals, the generation and elimination of Hcy stays in balance; 
however, once this homeostasis is disturbed, it leads to HHcy (75). HHcy can be 
developed via consumption of an excess amount of MET-rich diet, vitamin B12/folate 
deficiency, the occurrence of heterozygous/homozygous CBS gene mutation, and the 
obstruction of renal clearance (12). Besides these, genetic mutations in any Hcy 
metabolism pathway-regulated genes (e.g., 677C>T and 1298A>C in the MTHFR gene) 
can also lead to HHcy (14,76-78) (Table 1). Other determinants as well, such as age, 
sex, physical activity, alcohol intake, certain medications, and even different disease 
conditions can offset the rate of MET-cycle, thereby influencing the corresponding 
increase in the total Hcy levels in the blood (79). During HHcy, the MET-cycle is 
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generally dysregulated (80). This leads to disruption of multiple signaling pathways 
because it is the only pathway that gives rise to the production of essential methyl 
groups needed for the subsequent biosynthesis of cellular compounds such as creatine, 
epinephrine, carnitine, phospholipids, proteins, and polyamines and also the 
epigenetically governed cellular processes like methylation of DNA, RNA, and histones 
that are dependent upon Hcy metabolism (7,81). Although HHcy conditions can cause 
multi-organ pathologies via oxidative and ER-stress responses (7,20,82-84), the precise 


























HHcy Thrombosis (87) 
MTHFR 
C677T Ala223Val HHcy Retinal vein occlusion (88) 
C677T Ala223Val HHcy Stroke (89-92) 
C677T Ala223Val HHcy Venous thromboembolism (93) 
C677T Ala223Val HHcy Hypertension (94-96) 
C677T Ala223Val HHcy Alzheimer's Disease (97) 
A1298C Glu429Ala HHcy 
Cerebral venous sinus 
thrombosis 
(98-100) 
C677T Ala223Val HHcy Hyperlipidemia (101) 
C677T Ala223Val HHcy Diabetic nephropathy (102-105) 




C677T Ala223Val HHcy Parkinson's Disease (107,108) 
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Table 1. List of most prevalent genetic polymorphisms/mutations reported in HHcy and 
associated Diseases/Phenotypes. 
 
Metabolism of Hcy depends on several factors, i.e., the level of methionine in the 
diet, SAM level and the type of cells in which methionine metabolism takes place (109). 
High SAM level can act as an allosteric inhibitor for methylenetetrahydrofolate reductase 
(MTHFR). MTHFR catalyzes the conversion of 5,10-MTHF to 5-MTHF, which is a co-
substrate of Hcy in the remethylation reaction (110). Therefore, the presence of high 
SAM prevents Hcy from entering the remethylation pathway. High SAM level also acts 
as an allosteric activator CBS the transsulfuration pathway (111,112). Together it 
appears that the presence of high level of SAM favor Hcy entering to the transsulfuration 
pathway. However, only a few organs such as the liver, kidney, pancreas, brain, adipose 
tissue and small intestine express CBS (113,114). Vascular and muscle tissues don’t 
express CBS, so the high SAM lead to transient accumulation of Hcy (82). Hcy 
metabolism also depends on dietary MET load (115-117). When diet contains a basal 
methionine level, Hcy cycles through remethylation pathway about 1.5-2.0 times before 
being directed towards the transsulfuration pathway, but when dietary methionine 
content is half the basal level, the cycling of Hcy via the remethylation pathway 
increases 2-fold (118). Conversely, when the dietary MET level is high, Hcy cycling 
through the remethylation is reduced by about 1.5-fold (118). High levels of intracellular 
Hcy exported out into the circulation (119); however, the exact mechanism of Hcy export 
is not identified yet.  Although HHcy is found in ~5-7% of the general population and is 
associated with increased risk of cardiovascular disease, osteoporosis, skeletal muscle 
myopathy and other metabolic complications (7,20,82-84), the precise molecular 
pathways that lead to multi-organ dysfunction remain mostly unexplored. 
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2. Skeletal muscle structure and functions 
Skeletal muscle is the largest organ (roughly 40 to 50% of the body’s total weight 
in an average human), constitutes 50-75% of the body's total proteins (120-122). Muscle 
contains very long multinucleated cells (myocytes) that are bundled up and surrounded 
by connective tissues (123). Primary functions of skeletal muscle are: 1) production of 
contractile force that provides breathing, locomotion and postural support; and 2) 
thermogenesis during periods of cold stress (123). For force production, depending on 
the primary function of the muscle it consists of either fast twitch (type I) or slow twitch 
(type II) fibers (123). Type I fibers are used for repetitive, low-intensity functions, such as 
postural support (123). These fibers provide less force generation but are fatigue-
resistant and have a higher reliance on oxidative metabolism and therefore have more 
density of mitochondria and oxidative enzymes (123). Type II fibers are divided into two 
fiber subsets: type IIx and type IIa (123). Type IIx fibers are very glycolytic and produce 
high contractile force but are susceptible to fatigue due to a lower mitochondrial density 
(123). Type IIa fibers are an intermediate fiber type (123). They provide a moderate 
contractile force and are more fatigue-resistant than Type IIx fibers (123).  
Myocytes, unlike most other cell types, contain multiple nuclei and are striated 
because of contractile segments called sarcomeres (123). Within each muscle fiber, a 
structure called myofibril that contains the contractile protein of the muscle called actin 
and myosin (123). Actin filament consists of two additional proteins known as troponin 
and tropomyosin, which are used for contractile regulation (123). The striated regions, 
called sarcomeres, are within the myofibrils and consist of areas of myosin/actin overlap, 
as well as an area where myosin does not overlap with actin, called the H zone (123) 
(Fig. 3). Sarcomeres are divided by a wall of structural proteins, which makes up a 
region of the sarcomere called the Z line (123). Based on "sliding filament theory," during 
         9 
contraction, the required energy comes from the de-phosphorylation of adenosine 
triphosphate (ATP), wherein myosin heads "cock" form cross-bridges with actin and then 
pivot inward towards the H zone (124), that ultimately decreases the sarcomere length 
from one Z line to another Z line (Fig. 3) (125). 
 
Figure 3: Structure of a muscle fiber, organization of myofibril, and banding pattern. 
Surrounding each myofibril is a network of channels that serve as a storage site 
for calcium, which is crucial for the regulation of muscle contraction (126). This structure 
is called the sarcoplasmic reticulum (126). The transverse tubules are another set of 
channels that pass through the muscle fiber (126). Each myocyte is connected to a 
branch of a motor neuron through a neuromuscular junction serving as the site of 
electrochemical transmission (127). Collectively, all the myocytes that are innervated by 
a single motor neuron are termed as a motor unit (127). Upon generation of an action 
potential high enough to cause contraction, the neural impulse is transmitted to the 
myocyte through the neuromuscular junction and is propagated down the transverse 
tubules to the sarcoplasmic reticulum, causing Ca++ to be released (128). Ca++ binds to 
the troponin molecule, which creates a shift in tropomyosin position (128). This allows for 
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exposure of the actin active sites and myosin-actin cross bridge formation, resulting in 
contraction (128).  
In adults, repair of degenerated muscles relies on a small population of skeletal 
muscle stem cells known as satellite cells (129). Satellite cells, a population of 
quiescent muscle precursor cells, reside beneath the basal lamina, providing the 
predominant source of additional myonuclei for muscle growth (130,131). Once 
activated, satellite cells give rise to myoblasts that proliferate, differentiate, and fuse to 
form new muscle fibers or to repair damaged muscle fibers (132,133). The availability 
of a pool of myoblasts for myogenesis is essential for the development of muscle  
(134). The decreased number of muscle fibers could be due to the reduced myoblast 
proliferation or cytotoxicity (134). Moreover, in most cases, the apoptosis of myoblasts 
serves as a physiological behavior to remove excess myoblasts during myogenesis or 
muscle regeneration, while inappropriate apoptosis will pathologically lead to 
degeneration that is associated with various muscular dystrophies and atrophies 
(135,136). Therefore, identification of the molecular mechanism(s) of how high Hcy 
induced myoblast cytotoxicity is essential in understanding skeletal muscle growth, 
disease, and regeneration during HHcy condition. 
 
3. Hyperhomocysteinemia-mediated skeletal muscle pathophysiology 
HHcy is a known risk factor for vascular diseases (137); however, several studies 
also reported that HHcy leads to skeletal muscle weakness and functional impairment 
(5,15,20,21,46,66,82). Children born with severe homocystinuria due to CBS deficiency 
exhibit reduced body weight, skeletal muscle myopathy, and die teenage years 
(7)(5,15,20,21,46,66,82). Previous studies from our group showed that genetically 
modified HHcy mice (heterozygous for CBS gene deficiency) have lower body weights 
and less fatigue resistance and produce less contractile force, contain lower muscle ATP 
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levels, low dystrophin, and mitochondrial transcription factor A (mtTFA) (82). Similarly, in 
a study, Kanwar et al. [1976] found that HHcy can cause focal fragmentation, disruption, 
and smearing of the Z‐discs and disorganization of the myofilaments in the skeletal 
muscles (15). This study also showed that HHcy could reduce cellular metabolic activity 
and induce energy imbalance in gastrocnemius rat skeletal muscle by decreasing the 
activity of pyruvate kinase, creatine kinase, and noticed increased activity of succinate 
dehydrogenase (18). Similarly, Veeranki et al. [2015] showed that Hcy affects fatty acid 
oxidation, affecting energy metabolism in skeletal muscle via PGC‐1α specific protein 
nitrotyrosylation and a concomitant reduction in association with PPAR-γ (82). On the 
other hand, many neurological disorders like amyotrophic lateral sclerosis (ALS) and 
multiple sclerosis affect muscle degeneration, and these medical conditions are also 
connected to HHcy (16). HHcy significantly lowers physical functions by deteriorating 
skeletal muscle functions in older compared to age-matched healthy subjects (138), 
which suggests that aging is one of the potential risk factors to be considered in this 
process (139). 
Disorders, such as muscular dystrophy, sarcopenia, and immobilization, have 
been extensively researched. However, there is not enough data available considering 
the effects of HHcy on these conditions. Swart et al. [2013] demonstrated that in elderly 
individuals (~75.6 years of age), plasma Hcy levels had a strong inverse correlation with 
grip strength and functional capabilities (140). High Hcy levels resulted in poor grip 
strength in men and lowered functional ability including walking, climbing stairs and 
rising from a chair (140). In heterozygous CBS-deficient mice (CBS+/-), a model of mild to 
moderate HHcy, it was observed that 28 days post-induction of hindlimb ischemia CBS+/- 
mice displayed blunted hindlimb perfusion and lower collateral blood vessel 
development when compared to WT mice (46). This study also found that CBS+/- mice 
had lower vascular endothelial growth factor (VEGF), hypoxia-inducible factor (HIF1-α) 
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and peroxisome proliferator-activated receptor coactivator 1-α (PGC1-α) after 28 days of 
ischemic recovery when compared to controls (46). Below, I have summarized the 
findings relevant to oxidative/ER-stress, apoptosis, atrophy and poor angiogenesis 
caused by HHcy that might contribute to skeletal muscle dysfunction. 
 
3.1. HHcy-mediated oxidative/ER-stress responses in skeletal muscle 
During metabolic processes, a certain amount of pro-oxidative reactive oxygen 
species (ROS) are formed. The intracellular environment is predominantly a reducing 
environment due to the presence of enzymes like glutathione peroxidase (GPx), 
superoxide dismutase (SOD), and catalase (CAT), which break down ROS into water 
and oxygen.  There are also a series of built-in redox defense systems that inactivate 
ROS, which include reduced glutathione (GSH), hydrogen sulfide (H2S), nicotinamide 
adenine dinucleotide - hydrogen (reduced) (NADH), thioredoxin, and free radical 
scavengers such as Vitamins C and E (141-143). Oxidative stress occurs when there is 
an imbalance between free radical production and antioxidant capacity in a given cell. 
Previous studies revealed that Hcy contains a -SH group like other thiols (RSH) which 
can undergo oxidation to form a disulfide bond (RSSR) even at physiological pH in the 
presence of metal catalysts and molecular oxygen [O2°] (21) (Fig. 4). Further, Hcy can 
also produce hydrogen peroxide (H2O2, a pro-oxidant molecule) during metal-catalyzed 
oxidation step and peroxynitrite (ONOO-, a potent oxidant) in the presence of nitric oxide 
(NO) and superoxide anion (.O2-) (144). Findings from our group and others 
demonstrated HHcy effects on oxidative stress in cardiac microvascular endothelial cells 
(24), vascular smooth muscle cells (25), and the liver tissue (26). Although these 
phenomena have been studied in multiple tissue types, whether HHcy exerts its 
detrimental effects on muscle through similar mechanisms is not known. 
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Figure 4: Redox imbalance during hyperhomocysteinemia: (A) Homocysteine can 
homo/hetero-dimerize in the presence of transition metal catalysts and molecular oxygen 
to form superoxide radicals that are converted to H2O2 by superoxide dismutase (SOD) 
and which are in turn neutralized to H2O and O2 by glutathione peroxidase (GPx) and 
catalase (CAT).  
 
Several studies have reported that HHcy creates oxidative stress that promotes 
apoptosis, inflammation, insulin resistance, and dysregulation of lipid metabolism in 
different organs (5,7,145,146). Moreover, increased ROS level due to HHcy can be 
involved in lipid peroxidation, protein denaturation, and DNA damage, which ultimately 
damage cellular components; modulates gene expression, alters cell signaling 
pathways, and energy imbalance (147). Besides, Hcy can also form Hcy‐thiolactone and 
acetylates free amino groups in proteins, which further intensify the exaggerated 
oxidative stress condition (146). DiBello et al. [2010] showed that proteins (PRDX1, 
PRDX2, and HSP90AA) which are produced as a response to oxidative stress were 
significantly upregulated in the liver during HHcy (148). One study showed that 
production of ROS was ameliorated by PPAR‐γ activation in ECs (146), as reported 
previously from our laboratory indicating that PPARγ was reduced in HHcy condition 
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(148), suggesting that PPAR‐γ can be used as a potential target to mitigate oxidative 
stress during HHcy. HHcy lead to oxidative stress and that interferes with different 
cellular signaling pathways in various organs; therefore, it suggests that HHcy may have 
similar pathological effect in muscle tissue. 
Oxidative stress has been implicated in many diseases associated with protein 
misfolding pathways (28-33). Indeed, a study by Malhotra et al. [2008] showed that 
antioxidants reduce endoplasmic reticulum (ER) stress and improve protein secretion in 
Chinese hamster ovary (CHO)-H9 cells (149). Similarly, a study using differential display 
analysis in HUVECs found that GRP78 (78-kDa glucose-regulated protein) was 
upregulated in Hcy-treated HUVECs compared to controls (150). GRP78 is a chaperone 
protein belonging to the HSP70 family and predominantly resides in the lumen of the ER 
(151). HHcy can induce ER-stress (33), but which pathways get affected by this 
condition is poorly understood. It is known that after translation protein folding occurs 
inside ER, but during stress conditions, misfolded proteins accumulate inside the ER-
lumen and induce unfolded protein response (UPR) (152). UPR increases transcription 
of chaperone genes to facilitate protein folding, helps to attenuate the translation 
process, and finally, it degrades misfolded proteins accumulated in ER (153-155). In the 
mammalian system, UPR is mediated through inositol-requiring protein 1 (IRE1), PRKR-
like ER kinase (PERK), and activating transcription factor 6 (ATF6) (156). IRE1 
promotes X-box binding protein 1 (XBP1) mRNA splicing, which finally activates ER 
chaperones (e. g. BiP/GRP78, EDEM, and ERdj4). PERK phosphorylates eukaryotic 
translation initiation factor 2α (eIF2α), and that stops translation. ATF6 regulates the 
expression of chaperone genes and ER-associated degradation (ERAD) genes (157-
159). Several studies showed that HHcy could exacerbate ER-stress by reducing the 
efficiency of protein folding pathways and increasing the production of misfolded proteins 
(28). ER-stress might play a key role in mediating adverse effects during the HHcy 
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condition in muscle (160).  
 In the mammalian system, there are two isoforms of IRE1: IRE1α and IRE1. 
Both of these proteins are transmembrane proteins and contain a Ser/Thr kinase domain 
and an endoribonuclease domain (161,162). In a stress-free environment, IRE1α 
remains in an inactivated form bound with GRP78; however, in stress condition, it 
dissociates from GRP78 and gets auto-phosphorylated (163). Then the endonuclease 
activity of activated IRE1α cleaves a 26bp intron from ubiquitously expressed XBP1u 
mRNA. Removal of this intron causes a frameshift in the XBP1 coding sequence, 
resulting in the translation of XBP-1s isoform (152). XBP-1s encodes a specific basic 
leucine zipper-containing transcription factor, known as X-Box Binding Protein-1 (XBP1) 
to promote cell survival (163-165). However, during severe ER-stress conditions, IRE1α 
recruits' TNF receptor-associated factor 2 (TRAF2) and apoptosis signal-regulating 
kinase 1 (ASK-1), then activates c-Jun N-terminal kinase (JNK) and induces apoptosis 
(34-36). Although many studies also reported bidirectional regulation of ER-stress in 
apoptosis through JNK activation, and concomitant attenuation of cell proliferation and 
protein synthesis via PI3K/AKT axis (166-168), it is unknown whether HHcy exerts its 
detrimental effect in muscle through this similar mechanism pathway (Fig. 5).  
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Figure 5: HHcy-mediated cellular stress responses. (A) HHcy-mediated excessive 
production ROS impaired biogenesis, as well as protein folding process leading to ER-
stress, (B) Activation of IRE1α during ER-stress response, causes XBP1 mRNA splicing. 
During severe ER-stress condition activated IRE1α recruits’ TNF receptor-associated 
factor-2 (TRAF2) along with apoptosis signal-regulating kinase-1 (ASK1), which further 
activate c-Jun N-terminal kinase (JNK). (C) Activated JNK phosphorylates c-Jun, that 
recruit activator protein-1 (AP-1) to the promoter sequences of various pro-apoptotic and 
pro-inflammatory genes and induce cell deaths. (D) JNK is also involved in the 
phosphorylation of IRS-1 at Ser307 which in turn inhibits IRS-1 signaling thus impairing 
the PI3K/AKT axis and interfere with cell survival. 
 
3.2. HHcy-mediated cell death pathways 
Apoptosis is programmed cell death and is required for normal development; 
however, a very high amount of apoptotic cell death due to environmental stress can be 
detrimental (169). Excessive apoptosis is observed in many well-known disease states 
such as ischemic heart disease, AIDS, Alzheimer's, and Parkinson's, etc. (170-172). 
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Apoptosis occurs in 2 phases; namely, the death decision phase and execution phase. 
Death decision phase is controlled by two proteins, such as pro-apoptotic (Bax and Bak) 
and anti-apoptotic proteins (BCL-XL and BCL-2). The execution phase is regulated by 
caspases (proteolytic enzymes), responsible for the execution of apoptosis after the 
death decision is confirmed (173). Unlike necrosis, apoptosis occurs at a single cell level 
(173). Studies showed that an increase in oxidative stress could lead to caspase 
activation (174-177). This oxidative stress-mediated apoptosis was further supported by 
other studies demonstrating that anti-oxidants such as N-acetylcysteine (NAC) treatment 
could block apoptosis in a similar way that caspase inhibitors do (178,179). Several 
mechanisms(s) have been proposed pointing to the fact that oxidative stress generated 
by HHcy can lead to multiorgan pathologies (5,7,145,146). This argues that stimulus no 
other than redox imbalance during HHcy is capable of inducing apoptotic cell death. 
Even though findings have suggested that HHcy could be causal in a wide range of 
disorders including skeletal muscle myopathy; however, whether Hcy mediates skeletal 
muscle myopathy via inducing different types of cell deaths (apoptotic, necrotic and 
pyroptotic) are needed to identify. 
Studies showed that Hcy induced apoptotic cell death in ECs (180,181). A 
previous finding revealed that Hcy causes apoptosis in HUVECs via activation of UPR, 
which was mediated through IRE1 activation (182). Similarly, another study suggested 
that Hcy can induce trophoblast cell death during embryonic development (183). Hcy 
was also found to induce apoptosis in bone marrow mesenchymal stem cells (BMSCs) 
via oxidative stress mediated JNK activation (184). Folate deficiency, which is one of the 
causes of HHcy found to induce apoptotic cell death in RINm5F pancreatic Islet β–cells, 
through oxidative-nitrosative stress (185)(186). Mesangial cell apoptosis via inducing 
ROS and p38-MAPK activation had also been reported (187). Hcy induces apoptosis via 
upregulation of DNA damage response in neurons; this process is mediated through 
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PARP activation, and p53 induction (188). Our lab using genetically engineered 
heterozygous CBS deficiency mouse model (CBS+/-) reported that HHcy causes cell 
death via upregulation of mitochondria-mediated cell death pathway (BAX, caspase-9, 
and caspase-3) (189). Hydrogen sulfide (H2S) is known to be involved in the modulation 
of many physiological pathways. A study found that H2S-releasing sildenafil (ACS6) 
treatment could protect HHcy-mediated apoptosis in PC12 cells (190).  
 
3.3. HHcy-mediated dysregulation of angiogenesis 
Although many studies have been conducted to identify the possible 
mechanism(s) of skeletal muscle myopathy, fewer studies have demonstrated the 
potential risk factors that inhibit skeletal muscle adaptability in response to chronic 
ischemia. Poor angiogenic capacity is known to play a vital role in skeletal muscle 
adaptability (191,192). Lack of revascularization is already reported in elderly frailty and 
in many metabolic disorders, where metabolic factors and associated signaling 
pathways are found to be involved in a variety of skeletal muscle dysfunctions (193). 
Besides these, HHcy is well-studied in the cardiovascular system where it has been 
shown to increase oxidative stress in vascular tissue and cause dysfunction of ECs 
(194,195).  
The purpose of capillaries is to serve as the interface for delivery of oxygen and 
removal of metabolites to/from tissues. Angiogenesis is a physiological process where 
new blood vessels form from the pre-existing ones (191). Angiogenesis plays a vital role 
during tissue injury/wound repair, endometrial cycle, and muscle adaptation to 
stress/exercise (196). Previous studies demonstrated that HHcy impairs angiogenesis in 
multiple tissues (197-201). During angiogenesis, the main angiogenic signal is vascular 
endothelial growth factor (VEGF). VEGF production is mainly up-regulated in a tissue 
under hypoxic conditions via inducing hypoxia inducing factor 1 (HIF1) and that plays 
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a pivotal role in angiogenesis. VEGF binds to VEGF receptor (VEGFR) on ECs’ surface 
which goes through promotes ECs’ growth and migration towards the source of VEGF 
(202). Upon VEGF binding to VEGFR, PI3K is also activated leading to activation of the 
protein kinase Akt, which in turn phosphorylates eNOS and increases NO production 
during angiogenesis as shown in Fig. 6. Akt activation can also promote endothelial 
proliferation and cell survival.  
 
Figure 6: Hypoxia mediated angiogenesis via VEGF/Akt axis. Under hypoxic condition, 
VEGF production is up-regulated in tissue under hypoxic conditions via inducing hypoxia 
inducing factor 1 (HIF1) and that plays a pivotal role in angiogenesis via activating 
multiple angiogenic signaling cascades for endothelial cell proliferation, migration, and 
survival. 
 
An early study showed that Hcy treatment on chicken embryos (embryonic day 
3.5) caused inhibition of early extraembryonic vascular development, altered 
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composition of the vascular beds, and reduced VEGF-A and VEGFR-2 expression (200). 
Similarly, when HUVEC cells were treated with Hcy, it reduced cell proliferation and 
viability, induced a G1/S arrest, and attenuated the cell migration and tube-like formation 
on Matrigel (201). This study showed that this effect is mediated through VEGF/VEGFR, 
Akt, and ERK1/2 inhibition (201) as shown in Fig. 6. Similarly, a study demonstrated that 
Hcy inhibits angiogenesis by preventing proliferation and migration of ECs in a dose-
dependent manner (199). In an in-vivo rat model, it was reported that HHcy impaired 
ischemia-induced angiogenesis and collateral vessel formation, which is partly mediated 
through the reduction in bioactivity of endogenous NO (197). Several groups showed 
that Hcy-mediated defective angiogenesis is largely due to decreased GPx expression 
and a consequent increase in oxidative stress, leading to endothelial progenitor cell 
dysfunction (203,204), reduction of the bioavailability of NO (205,206) and dysregulation 
of matrix metalloproteinases (MMPs) (207,208).  
Previous studies showed that high Hcy can be toxic to endothelial cells and can 
induce endothelium dysfunction may be via hypomethylation of specific genes (209-
212). It also noticed that Hcy affects ECs via inhibiting cyclin A (213). When they 
transduced cyclin A in ECs, the inhibitory effect of Hcy was rescued. These studies have 
been conducted in an in-vitro system; however, there is much less evidence reported for 
the in-vivo system. As Akt has been associated to involved in ECs proliferation, 
migration and survival during angiogenesis and HHcy found to inhibit Akt activation in 
ECs, however, whether these two processes potentiate muscle atrophy is not studied yet 
(37,45). 
 
3.4. HHcy-mediated skeletal muscle atrophy 
As mentioned earlier, skeletal muscle is the largest organ in our body, containing 
50-75% of the body's proteins. Loss of skeletal muscle mass is commonly referred to as 
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muscle atrophy. Several E3 ubiquitin ligases such as MuRF1, MAFBx (Atrogin-1), 
Nedd4.1, TRAF6, and MUSA1 have been identified to mediate proteolytic degradation of 
both thick and thin filament proteins in skeletal muscle atrophy (214,215).  Forkhead Box 
(FOX) proteins are a group of transcription factors with a conserved DNA binding 
domain and are responsible for regulating a number of E3-ubiquitin ligases upon a 
variety of cellular stress responses (216-219). Studies showed that in the absence of 
growth factors or in the presence of external stress (oxidative/ER-stress), PI3K/Akt 
pathway activation decreases and JNK activation increases; which promote nuclear 
localization of Foxo (216,220-223) as shown in Fig. 7. Although nuclear localization of 
FOXO stimulates MuRF-1 and Atrogin-1 expression, and that induces muscle atrophy 
(224), however, whether HHcy also causes skeletal muscle atrophy via this similar 
mechanism was not studied (Fig. 7). 
 
Figure 7: Schematic model of HHcy-induced muscle atrophy via nuclear translocation 
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of FOXO. In HHcy condition, JNK activation may be upregulated and Akt-activation 
may be downregulated, which promotes nuclear localization of FOXO and reduced 
activation of mammalian target of rapamycin (mTOR). Nuclear localization promotes 
upregulation of MuRF-1 and Atrogin-1, which finally degrade muscle proteins. 
Whereas reduced activation of mTOR reduced protein synthesis. Muscle atrophy 
causes, when protein degradation exceeds over protein synthesis over time.  
 
It has been reported that HHcy is associated with a decline in physical 
performance and skeletal muscle dysfunction in genetically engineered CBS deficient 
mice (CBS+/-) (5,20,82). Skeletal muscle dysfunction and poor physical performance 
can result from a reduction of muscle mass and/or structural and metabolic alteration 
(Fig. 7) (139,225,226). Indeed, a study found that cystathionine γ-Lyase-deficient mice 
have lethal myopathy and oxidative injury, wherein dietary cysteine supplementation 
could mitigate this effect (84). Another group reported patients with HHcy due to 
methyltetrahydrofolate reductase (MTHFR) mutations (C677T and A1298C) showed 
poor survival and muscle pain in these patients (227). Similarly, a study from our group 
concluded that vasodilation in skeletal muscle arterioles is decreased during HHcy due 
to reduced expression of gap junction proteins such as connexins 37, 40 and 43, and 
increased expression of myostatin in the skeletal muscle (228).  
 
4. Effect of hydrogen sulfide on hyperhomocysteinemia-mediated skeletal muscle 
myopathy 
Hydrogen sulfide (H2S) is increasingly being recognized as a novel endogenous 
gasotransmitter like nitric oxide (NO) and carbon monoxide (CO) (54,59,229). Being a 
potent anti-apoptotic/anti-necrotic (230,231), anti-inflammatory (232) and cytoprotective 
agent (233), H2S plays crucial roles in physiological homeostasis wherein it reduces 
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oxidative damage (51,234). As mentioned earlier, high SAM level can act as an allosteric 
inhibitor for MTHFR in the remethylation pathway (110) and allosteric activator for CBS 
in the transsulfuration pathway (111,112). Together these results suggest that the 
presence of a high level of SAM favors Hcy entering into the transsulfuration pathway; 
however, in patients with CBS mutation, a high SAM level builds up (due to MET load) 
leading to transient accumulation of Hcy and reduction of H2S levels. The endogenous 
H2S production ranges from 1–10 pmoles per second per mg protein (235). Patients with 
CBS mutation have a high amount of Hcy and tend to produce a lesser amount of H2S 
(63,236), suggesting that these patients are likely more prone to oxidative stress-
mediated damage (54). Studies revealed that endogenous H2S could modulate multiple 
signaling pathways, upregulate endogenous antioxidant systems and exert additive 
effects with known antioxidants (234), suggesting that exogenous supplementation of 
H2S could be employed as a beneficial strategy to improve redox imbalance owing to 
HHcy (Fig. 8). 
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Figure 8: Salubrious effects of H2S on cellular biochemistry. (A) Being an important 
antioxidant molecule H2S helps synthesize cysteine which gets converted into GSH via 
CBS and CSE enzymatic pathways. (B) H2S is a potent scavenger for a variety of 
reactive oxygen species (ROS). (C) H2S is known to reduce disulfide bonds in proteins 
and thereby it may reverse the homocysteinylation of proteins during HHcy conditions. 
 
4.1. The effect of Hydrogen sulfide on oxidative/ER-stress responses 
Multiple studies demonstrated the cytoprotective effects of H2S in different in-vitro 
models, all relating to its ability to neutralize a variety of reactive species (25,237,238) 
and reduction of a disulfide bond in proteins (54,239) (Fig. 8). H2S in water dissociates 
into H+, HS−, and S2− ions. HS− has a capacity to scavenge ROS. H2S itself has also 
been recognized to be a reducing agent, as it can react directly with and quench the 
superoxide anion (O2−) (240,241) and free radicals like peroxynitrite (242) as well as 
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other ROS in-vitro. Micro concentrations of H2S generated from Na2S/NaHS was found 
to neutralize free oxyradicals (243), peroxynitrite (237), hypochlorous acid (238) and 
homocysteine (25) in in-vitro condition. There is no sulfide receptor in mammalian cells 
that is responsible for the biological actions of sulfide, hence sulfide, as a thiol with 
strong reducing activities, may also be a redox-controlling molecule similar to other small 
thiols, such as cysteine and GSH (237,244). A study by Kimura et al. (2004) using 
primary cultures of neurons, found that H2S increases the cellular GSH levels by 
enhancing the activity of gamma-glutamylcysteine synthetase and up-regulating cystine 
transport (244). Similarly, another study reported that 100 μM NaHS induces glutamate 
uptake by assisting glial glutamate transporter-1 (GLT-1) and enhances cysteine 
transport and GSH synthesis (245).  In support of this effect, multiple studies 
demonstrated that H2S induces the cellular GSH in the brain (246), spinal cord (247), 
heart (248), lung (249), kidney (250), liver (249), and gastrointestinal tract (251,252). 
Moreover, recent reports suggested that H2S could attenuate cellular oxidative stress by 
improving activities of CAT (248,253-255) and GPx (256-258).  
Many studies showed that H2S attenuates ER-stress in numerous tissue types. A 
study found that H2S attenuated HHcy-induced cardiomyocytic ER-stress in rats (259). 
Whereas, Li et al. (2015) demonstrated that H2S protected against myocardial 
ischemia/reperfusion injury in rats by inhibiting ER-stress (260). Likewise, another study 
also reported that H2S exerts its protection against the neurotoxicity of formaldehyde by 
overcoming ER-stress in PC12 cells (261).  
 
4.2. The effect of Hydrogen sulfide on cell death pathways  
In addition to an anti-oxidant effect of H2S, several studies also proposed that it 
has the ability to reduces cell death in various tissue types. An in-vitro study using 
nucleus pulposus (NP) from patients with lumbar disc herniation showed that exogenous 
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H2S donor attenuated hypoxia (generated by CoCl2 treatment) induced apoptosis in 
primary NP cells (262). Similarly, a study using a rat model found that H2S mitigates 
cigarette smoke-induced apoptosis via reducing ER-stress (263). H2S was also reported 
to decrease Hcy-mediated ER-stress and apoptosis in the hippocampus of rats by 
enhancing the BDNF-TrkB pathway (264). In support of this, NaHS supplementation was 
shown to significantly inhibit hypoxia-induced neuronal apoptosis through inhibition of 
ROS (mainly H2O2)-activated Ca2+ signaling pathway in mouse hippocampal neurons 
(265). In another study, it was observed that H2S attenuated gentamicin-induced 
apoptosis via reducing ROS moiety in normal rat kidney-52E cells; they found the 
protein levels of Bax, Caspase-3, and cleaved-caspase-3 were decreased while the 
expression of Bcl-2 was increased (266). Similarly, NaHS (H2S donor) administration 
significantly inhibited the early phosphorylation of JNK and decreased the number of 
apoptotic cells, lowered cytochrome C release and enhanced Bcl‐2 expression in 
cardiomyocyte after ischemia-reperfusion (I/Re) injury (267). H2S also attenuated 1-
methyl-4-phenylpyridinium ion (MPP (+))-induced apoptosis in PC12 cells by attenuating 
an overproduction of intracellular ROS (268). Exogenous NaHS (H2S donor) also shown 
to ameliorate early brain injury after subarachnoid hemorrhage (SAH) by inhibiting 
neuronal apoptosis (268). 
 
4.3. The effects of Hydrogen sulfide on angiogenic defect 
It has been reported that H2S is also involved in vasodilation, vascular protection, 
regulation of blood pressure and many other functions (54,57-59,61). Like other 
gasotransmitters (CO and NO), H2S can rapidly travel to vascular tissues without any 
transporter exerting a host of biological responses. Two independent groups reported 
using either transformed endothelial cell line (RF/6A) or HUVECs that H2S induces 
proliferation and migration of these cells (269,270). The pro-angiogenic effect of H2S is 
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further supported by the increase in tube-like structure formation in ECs in in-
vitro Matrigel assays (269,270). H2S exerts angiogenic effects via releasing VEGF in 
both SMCs (smooth muscle cells) and ECs (271,272). Some in-vivo studies 
demonstrated that H2S induced a concentration-dependent increase in the length and 
complexity of the vascular network (269,270). When ECs were exposed to H2S donors, it 
activated multiple signaling pathways, such as PI-3K/Akt and MAPK pathways during 
neovascularization (269,270). Further evidence for H2S-mediated VEGF induction during 
angiogenesis was reported in an ex-vivo mouse aorta sprouting assay, where the VEGF-
induced angiogenesis was markedly suppressed in aortic rings of the CSE deficient mice 
(CSE-/-) (270). In an alternative pathway, exposure to H2S increased calcium levels in 
ECs, which led to eNOS activation and increased NO release during angiogenesis (273-
275).  
 
4.4. The effects of Hydrogen sulfide on muscle atrophy 
Skeletal muscles are now considered to be an endocrine organ, synthesizing 
and secreting a variety of bioactive molecules including inflammatory cytokines, growth 
factors, adipokines, carnitine and more recently H2S (276). In this context, H2S appears 
to protect against low oxygen and nutrient supply as well as ischemic injury in multiple 
organs including skeletal muscles (276-278). In agreement with this view, it was 
hypothesized that dysregulation of H2S metabolism is involved in chronic fatigue 
syndrome (CFS), also called myalgic encephalomyelitis (279). One of the cellular targets 
of H2S is potassium (KATP) channel (280,281). KATP channel activation has been 
suggested to be involved in the prevention of calcium overload and preservation of 
myofibre integrity during exercise, recovery from muscle fatigue, rather than in normal 
muscle contractility and excitability (282,283). Similarly, a significant decrease in H2S 
content in muscle fibers together with a reduction in SOD1 expression was presented in 
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CHAPTER II 
HYPOTHESIS AND SPECIFIC AIMS 
 
Key Objective 
The objective of this study was to determine the effects of 
hyperhomocysteinemia on skeletal muscle myopathy and investigate if H2S can 
attenuate these effects. 
Hypothesis 
The central hypothesis of this proposal is that HHcy causes skeletal muscle 
myopathy by inducing apoptosis, inflicting muscle atrophy and compromising 
angiogenesis via JNK-activation and concomitant impairment of PI3K/AKT axis, and H2S 
mitigates these effects (Fig. 9). 
Specific Aim#1: To determine whether HHcy induces ER-stress and apoptosis via JNK-
phosphorylation, effect(s) of H2S treatment in mitigating this induction. 
Specific Aim#2: To determine whether the Hcy-activated JNK downregulates 
angiogenic pathways via inhibiting AKT-phosphorylation and H2S treatment ameliorates 
these pathway(s). 
Specific Aim#3: To determine whether Hcy instigates muscle atrophy via up-regulation 
of E3 ubiquitin ligases through JNK/AKT axis and H2S attenuates muscle atrophy
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CHAPTER III 
HYDROGEN SULFIDE ALLEVIATES HHCY-MEDIATED OXIDATIVE AND ER-STRESS 
RESPONSES IN SKELETAL MUSCLE (284) 
 
INTRODUCTION 
Homocysteine (Hcy) is a sulfur-containing non-proteinogenic amino acid that is 
generated during methionine metabolism via the methionine cycle (MET-cycle) (285). In 
healthy subjects, synthesis and elimination of Hcy are balanced; however, if Hcy 
metabolism is disturbed, then its plasma levels are elevated, leading to 
hyperhomocysteinemia (HHcy) (20,82-84,286). Although children born with functional 
CBS deficiency show severe HHcy and die in their teenage years (13,15,20), the 
molecular mechanism(s) how HHcy triggers such pathological effects in skeletal muscle 
is not fully understood.  
Previous studies revealed that Hcy contains a -SH group like thiols (RSH) which 
can undergo oxidation to form a disulfide (RSSR) even at physiological pH in the 
presence of metal catalysts and molecular oxygen [O2°] (21). Further, Hcy can also 
produce hydrogen peroxide (H2O2, a pro-oxidant molecule) during metal-catalyzed 
oxidation step and peroxynitrite (ONOO-, a powerful oxidant) in the presence of nitric 
oxide (NO) and superoxide anion (.O2-) (144). Although these phenomena have been 
studied in multiple tissue types, whether HHcy exerts its detrimental effects on muscle 
through these mechanisms is not yet elucidated. Oxidative stress has been implicated in 
many diseases associated with protein misfolding (29-31). Likewise, studies have also 
reported that HHcy could induce ER-stress in hepatocytes as well as in vascular 
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endothelial and aortic smooth muscle cells, but the cellular pathways that are involved in 
these stress-related conditions are not adequately studied (32,33). It is well-known that 
after translation, the protein folding occurs inside the ER, but during stress conditions, 
misfolded proteins can accumulate inside ER-lumen inducing the unfolded protein 
response (UPR) (152). In mammals, there are three branches of UPR: inositol-requiring 
enzyme-1 (IRE1); PRKR-like ER kinase (PERK); and activating transcription factor-
6 (ATF6) (153,154,156). During severe ER-stress conditions, activated IRE1 recruits’ 
TNF receptor-associated factor-2 (TRAF2) and apoptosis signal-regulating kinase-1 
(ASK1), which further activate c-Jun N-terminal kinase (JNK) (34-36). Activation of JNK 
phosphorylates c-Jun at Ser63 and 73 residues in NH2-terminal (287,288). Upon 
activation, the phosphorylated JNK translocate to the nucleus where it phosphorylates c-
Jun (289,290). JNK along with c-Jun makes up the activator protein-1 (AP-1) 
transcription factor, which involved in the transcription of some pro-apoptotic and pro-
inflammatory genes (291-296). JNK also regulates maturation and activity of T cells in 
addition to the synthesis of pro-inflammatory cytokines, such as interleukin-2 (IL-2), IL-6 
and TNF-α (297-299). Whether HHcy can compromise muscle survival via JNK 
activation is not currently known.  
Chronic systemic inflammation and apoptosis are the important driver for muscle 
wasting, that can be dysregulated by HHcy condition (300). These cytokines work 
synergistically promoting muscle atrophy due to the cross-talk between inflammatory 
cells and organs, resulting in reduced protein synthesis and increased protein 
degradation, and ultimately leading to muscle loss and functional impairment. Therefore, 
identification of the precise molecular mechanism(s) as to how these cytokines are 
regulated during HHcy is essential to devise future preventive strategies.  
H2S is increasingly being recognized as an important signaling molecule in the 
cardiovascular and nervous systems via its ability to neutralize a variety of reactive 
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oxygen species (ROS) (25,237,238) and to reduce disulfide bonds (54,239). 
Cystathionine γ-lyase (CSE) and CBS can irreversibly remove Hcy by converting it into 
H2S, since patients with CBS lack H2S, making them vulnerable to oxidative stress-
mediated damages (54). Hence, the purpose of my study was to understand the effect(s) 
of HHcy-mediated oxidative and ER-stress responses in muscle and the beneficial 
effects of an H2S donor (NaHS) employing both in-vitro (C2C12 cells) and in-vivo model 
(CBS+/-) systems. My results indicate that H2S could be developed as a potential 
therapeutic target in various forms of musclulopathies wherein HHcy is linked with 
metabolic dysfunction. 
 
MATERIALS AND METHODS  
Animal maintenance and diet protocol. Male wild-type (WT, C57BL/6J) and 
CBS+/− (B6.129P2-Cbstm1Unc/J 002853) mice were purchased from the Jackson 
Laboratory (Bar Harbor, ME) (71). All animals were ∼8-12 weeks-old and maintained in 
12:12 h light–dark cycle with regular mouse chow diet in the animal facility of the 
University of Louisville. All animal protocols and care were carried out according to 
the guidelines of National Institute of Health (NIH Pub. No. 86–23, revised 1985) and 
were approved by the Institutional Animal Care and Use Committee (IACUC) of the 
University of Louisville. Animals were divided into 4 experimental groups: (1) Wild-type 
C57BJ/L6 mice (WT); (2) CBS+/− heterozygous mice fed with methionine (CBS+Met); (3) 
NaHS-supplemented wild-type mice (WT+NaHS); (4) NaHS-supplemented CBS+/−+Met 
mice (CBS+Met+NaHS). Mice were treated with NaHS for 8 weeks (30μM/kg/day, I.P.) 
and fed with a methionine-enriched and low-folate, low Vitamin B6, and low Vitamin 
B12 diet (Cat. No. TD 97345; Harlan Teklad, Madison, WI, USA) (301-304). WT mice 
were given 0.9% normal saline (vehicle control) and fed with normal chow (Purina 
Farmer's Exchange, Framingham, MA, USA).  
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Rationale for choosing the experimental mice. Homozygous for CBS knock out (KO) 
mice (CBS-/-) mice die shortly after their birth, whereas heterozygous for CBS KO 
mice (CBS+/-) survive but they show low Hcy levels in their blood (5-10 μM, Fig. 15D). 
So, in the present study, I treated CBS+/- mice with high met diet to examine the 
effects of HHcy condition (>40 μM, Fig. 16F) on skeletal muscle (301-304). 
Genotyping analysis of the heterozygous CBS+/− mouse. After purchasing, mice were 
cross-bred, yielding around 10 % CBS−/−, 60 % CBS+/−, and 25 % CBS+/+. For 
genotyping, tail samples were collected, genotypic analysis was performed using PCR 
by targeted disruption of the CBS gene. The PCR products were run on 1.2 % agarose 
gel (prepared in TAE buffer, pH 8.4) in the presence of ethidium bromide and the images 
recorded in a gel documentation system (305). CBS+/− heterozygote gene-positive mice 
produced two bands (450 and 308 bp), while CBS+/+ (WT) mice represented only one 
band (308 bp). 
Reagents and antibodies. Dulbecco's Modified Eagle's Medium (DMEM), fetal bovine 
serum (FBS) were purchased from American Type Culture Collection (Manassas, VA, 
USA) and trypsin EDTA was from VWR (Radnor, PA, USA). ECL reagent and 
polyvinylidenedifluoride (PVDF) membrane were from Bio-Rad (Hercules, CA, USA). 
Dihydroethidium (DHE) was purchased from Thermo Fisher Scientific (Waltham, MA, 
USA). All other reagents and chemicals were ordered from Sigma–Aldrich or available 
highest grade. 
The antibodies for GRP78 (Cat. No.# sc-13968), IRE1α (Cat. No.# sc-20790), 
ATF6 (Cat. No.# sc-22799), X-box binding protein (XBP1) (Cat. No.# sc-7160), rabbit 
anti-mouse (Cat. No.# sc-358914), mouse anti-rabbit (Cat. No.# sc-2357), and mouse 
anti-goat (Cat. No.# sc-2354) were ordered from Santa Cruz Biotechnology (Dallas, TX, 
U.S.A). The antibody for GAPDH (Cat. No.# MAB374) was ordered from EMD Millipore 
(Burlington, MA, USA). Rest of the antibodies for p-IRE1α (S724) (Cat. No.# ab48187), 
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p-JNK (T183/Y185) (Cat. No.# ab4821), t-JNK (Cat. No.# ab85139), p-cJun (S73) (Cat. 
No.# ab30620), and t-cJun (Cat. No.# ab32137) were ordered from Abcam (Cambridge, 
MA, USA), and used for Western blots analysis as per the manufacturers’ protocols.   
Cell culture and treatments. The C2C12 cells (immortalized mouse myoblast cell line, 
ATCC) were cultured in Corning® T-75 flasks in ATCC-formulated DMEM (catalog No. 
30-2002) supplemented with 10% FBS, 0.1% of penicillin and streptomycin at 37 °C with 
5% CO2. The C2C12 cells were grown to 80% confluence and were plated for 4 different 
experimental groups: Group 1: CT (PBS as vehicle control); Group 2: Hcy (1mM); Group 
3: Hcy+NaHS (250 µM); and Group 4: NaHS. In this study, we used 1mM Hcy and 
250µM NaHS concentrations for the individual treatments (20,246). A stock solution of 
Hcy, NaHS were prepared by directly dissolving in basal DMEM medium (serum-free 
media). Following 24 h of treatment as mentioned earlier, cells were processed for 
qPCR, Western blot, DHE-staining, and other biochemical analysis.  
Total RNA extraction. Total RNA was extracted from muscle samples and cells using a 
Trizol method (306). In brief, first equal volume of Trizol was added in the sample and 
incubated for 10mins in 250C. Then 200μl of chloroform was added and incubated for 
10mins on ice. After that, samples were centrifuged at 12000g for 15mins at 40C and 
carefully collected the top layer in a new Eppendorf tube containing 500uL of prechilled 
isopropanol. Then samples were centrifuged at 12000g for 20mins at 40C and pellets 
were collected in DEPC water. Total RNA quality was determined by NanoDrop ND-
1000, and RNA with high purity (260/280~2.00 and 260/230~2.00) was used for q-PCR. 
Reverse transcription and real-time quantitative PCR (RT-qPCR). Reverse transcription 
was performed according to the manufacturer’s protocol using high-capacity cDNA 
reverse transcription kit from Applied Biosystems (Foster City, CA, USA) for the primer 
sequences listed in Table 2. For RT-qPCR, SYBR green-based kit was used to measure 
the relative expression of each mRNA specific primers. Briefly, 3 steps cycling protocol 
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was performed using 20 ng of cDNA template in a 20μL reaction volume under the 
following conditions: denaturation at 95 °C for 15 min followed by 40 cycles of 94 °C for 
15 s, 55 °C for 30 s, and 70 °C for 34 s in which fluorescence was acquired and detected 
by Roche LightCycler® 96 Real-Time PCR System (Roche Diagnostics, IN, USA). 
Following RT-qPCR, analysis of melt curve was performed to validate the specific 
generation of the expected PCR product. GAPDH was used as an endogenous control 
(Quanta Biosciences, Beverly, MA, USA). 
  
Genes Forward Primers Reverse Primers 
GRP78 5’-ATTGGTGGCCGTTAAGAATG-3’ 5’-CAGTGTTGTCTCGGCCAGTA-3’ 
ERN1 5’-CCCAAATGTGATCCGCTACT-3’ 5’-TTGAGAGAATGCAGGTGTGC-3’ 
ATF6 5’-GGCCAGACTGTTTTGCTCTC-3’ 5’-CCCATACTTCTGGTGGCACT-3’ 
XBP1 5’-TGAATGGCCCTTAGCATTTC-3’ 5’-CACAGAACAGGACGCTGTGT-3 
 
Table 2. List of primers used for RT-qPCR experiments for chapter IV. 
 
Western blotting. All protein expressions of both tissues and cells were assessed by 
Western blotting (307). Briefly, all protein lysates were made in RIPA buffer, which was 
supplemented with PMSF (1 mM), Na-orthovanadate (1 mM) and a protease inhibitor 
cocktail (10 μl/ml of lysis buffer). The protein samples were estimated by Bradford assay. 
Equal amounts of protein (50 μg) were resolved on SDS-PAGE (8%, 10%, 12%) and 
transferred onto a polyvinylidene difluoride (PVDF) membrane. The blots were visualized 
using ECL Luminata Forte (Millipore, Temecula, CA, USA) in a Bio-Rad ChemiDoc 
system. The band intensity was normalized to GAPDH for all the proteins and quantified 
using the Bio-Rad’s Image Lab software (Bio-Rad, Hercules, CA, USA).  
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Total Homocysteine measurement. The total tHcy levels were measured from plasma of 
experimental mice using homocysteine assay kit (Crystal Chem, IL, USA) as per 
manufacturer’s instructions.   
Intracellular ROS imaging by confocal scanning microscopy. The cell permeable 
fluorescent dye dihydroethidium (DHE) was used to detect intracellular ROS (72). In 
brief, after treatment C2C12 cells were incubated in DHE (10μM/L) for 20 minutes in a 
humidified chamber at room temperature in the dark. At the end of the incubation, cells 
were washed with PBS and fluorescence images were scanned using a laser confocal 
microscope (Olympus FluoView1000, Pittsburgh, PA, USA) (72). Fluorescent intensity 
was quantified using ImageJ software (https://imagej.nih.gov/ij/).  
Assessment of lipid peroxidation. Malondialdehyde (MDA), a metabolite of lipid 
peroxidation and an indicator of oxidative stress was measured as the previously 
described method by Okhawa et al. (308). Briefly, after treatment, the cells were washed 
with PBS, followed by sonication (5 Amps/ 5 mins) and centrifugation at 13000 rpm for 
10 minutes. To the supernatant 100 μl of 8.1% SDS, 20% acetic acid, and 0.8% 
thiobarbituric acid were added. The samples were incubated at 95°C for 60 minutes, and 
then 100μl of deionized H2O and 100μl of 1-butanol were added. After spinning at 4000 
rpm for 10 minutes, the top layer was collected in 96 wells plate and read at a 
wavelength of 532 nm. The OD values were plotted against the known standard to 
determine the intracellular malondialdehyde levels.  
Assessment of hydrogen peroxide and total ROS. H2O2 was measured from cells by 
Amplex red assay kit (Invitrogen, Cat no. A22188) according to the manufacturer 
protocol. Whereas, 2', 7'–dichlorofluorescein diacetate (2’,7’-DCFDA) assay kit (Abcam, 
Cat no.-ab113851) was used for total cellular ROS detection. In brief, after treatment 
cells were washed two times with PBS and incubated with a 10 µM DCFDA probe for 15 
mins in serum-free media. Final fluorescence intensity was measured in a microplate 
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reader (Ex, Em= 485, 535nm). 
Measurement of GSH/GSSG ratio. Assessment of GSH vs. GSSG ratio was carried out 
in all 4 treatment groups using GSH/GSSG ratio detection kit (Abcam, Cat no.-
ab138881) according to the manufacturer protocol.  
Assessment of pro-inflammatory cytokines. Multi-analyte enzyme-linked immunosorbent 
assay (ELISA) kit (Qiagen, Germantown, MD, USA) was used following the 
manufacturer’s protocol to measure all the pro-inflammatory cytokines (IL1α, IL2, IL4, 
IL6, IL12A, IFN-γ, and TNF-α). 
Cell viability assay. Cell viability was determined by MTT assay (309). In brief, after 
treatment as described above, all media was aspirated and 100 μl MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] reagent solution was added in 
each well after diluting MTT reagent (5 mg/mL) in basal media. The cells were then 
incubated for 4 h at 37°C and then washed with PBS. After that, 100 μl of DMSO was 
added to each well to dissolve the cell membrane and bring formazan into the solution. 
The absorbance values were taken at 570 nm by Spectramax 3000 spectrophotometer 
(Molecular Devices, Sunnyvale, CA, USA). 
Flow cytometry. C2C12 cells were grown in 12 well plates until 70% confluence and 
treated as mentioned above. After 48 h, the cells were harvested with 150 µl trypsin-
EDTA (Corning) and 600 µl DMEM complete medium to neutralize the trypsin. The cells 
were collected in a 1.5 ml Eppendorf tube and spun at 2000 rpm for 5 minutes, and the 
supernatant was discarded. Then cells were washed 2 times with complete DMEM 
media to remove any traces of trypsin and then resuspended in 1x binding buffer (Sigma 
apoptosis kit: Cat # APOAF). The cells were then stained with Annexin V and Propidium 
Iodide (PI) according to manufacturer’s instructions and subjected to flow cytometric 
analysis (Accuri cytometers Inc. Ann Arbor, MI, USA).  
Statistics. All values are expressed as mean ± s.e.m. The overall difference between the 
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experimental groups was determined by one-way or two-way ANOVA, and a Tukey's 
post hoc analysis was run when overall statistically significant difference occurred in 
group means. Whereas, unpaired t-test was used for comparison between two groups. 
The threshold for significance was set at p<0.05, and a minimum of 3 biological 
replicates were used for each experiment. For all statistical calculation, GraphPad Prism 
(Ver 7, GraphPad Software) was used. 
 
RESULTS 
Hcy induces oxidative stress in C2C12 cells. DHE-staining results showed that Hcy 
significantly induced ROS in C2C12 cells as compared to vehicle controls (PBS treated), 
whereas, NaHS treatment mitigated the effects of Hcy (Fig. 10A). To detect intracellular 
total ROS levels, I used DCFDA fluorescent probe (an indicator for superoxide-, 
peroxide- and peroxynitrite-mediated oxidative chemistry). A similar finding was also 
observed in the levels of total ROS in Hcy treated cells compared to controls as 
measured by a fluorometric method (Fig. 10B). Hcy treatment showed significant 
induction of H2O2 production in C2C12 cells, and it was reduced by NaHS (Fig. 10C). 
Similarly, malondialdehyde levels (a marker of lipid peroxidation) was significantly 
increased upon Hcy treatment in C2C12 cells, and NaHS reversed this effect (Fig. 10D). 
Furthermore, a significant reduction in GSH/GSSG ratios in Hcy treated C2C12 cells as 
compared to controls, whereas NaHS treatment was found to successfully attenuate this 
effect (Fig. 10E). 
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Figure 10:  NaHS protects against Hcy-induced oxidative stress in C2C12 cells 
(immortalized mouse myoblast cell line). (A) 1mM Hcy treatment for 24h resulted in the 
generation of cellular oxidative stress in C2C12 cells as detected by dihydroethidium 
(DHE)-staining. Images captured using confocal microscope are on the left and their 
quantification on the right (under 60x, bar=20μm), where n=3 technical replicates; (B) 
Hcy treatment induces total ROS levels as detected by 2’,7’-H2DCFDA (2',7' –
dichlorofluorescin diacetate) probe, where n=4 technical replicates; (C) Hcy exposure 
induces H2O2 production measured by Amplex red assay kit,  n=3 technical replicates; 
(D) Hcy treatment induces lipid peroxidation measured by Malondialdehyde (MDA) 
assay, where n=3 technical replicates; (E) Hcy treatment reduces GSH vs. GSSG ratio, 
where n=3-4 technical replicates. The overall difference between the experimental 
groups was determined by one-way, and a Tukey's post hoc analysis was run when 
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overall statistically significant difference occurred in group means. Data are shown as 
means.e.m. and *p<0.05 vs. CT and #p<0.05 vs. Hcy. 
 
HHcy induces ER-stress responses in skeletal muscle. To examine whether HHcy 
induces ER-stress was via redox imbalance mechanism, I performed Western blot 
analyses on samples from both in-vitro and in-vivo models. Results showed that Hcy 
significantly induced ER-stress markers such as GRP78, ATF6 and p-IRE1α and that the 
effect was mitigated by NaHS in C2C12 cells as shown in Fig. 11A and 11B. However, I 
did not notice any significant changes in XBP1 protein levels after Hcy treatment (Fig. 
11A and 11B). In addition, the ratios of p-IRE1α/t-IRE1α were found to be significantly 
induced in C2C12 cells after Hcy treatment compared to controls, whereas NaHS 
supplementation attenuated this effect (Fig. 11C).  In the qPCR analysis, I noticed 
mRNA levels of GRP78, ATF6, IRE1α, and XBP1 were also increased significantly in 
post Hcy treatment of C2C12 cells compared with vehicle controls, these effects were 
also mitigated by NaHS (Fig. 11D). In addition, my in-vivo model revealed similar type of 
changes in Western blots and qPCR data from the protein samples collected from 
hindlimbs gastrocnemius muscle (Fig. 11E-H).
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Figure 11A-D: High Hcy mediates ER-stress response in muscle cells in-vitro. (A) 
Western blots analysis showing Hcy treatment induces ER-stress markers, such as 
GRP78, ATF6, p-IRE1α (S724), t-IREα and XBP1, whereas NaHS treatment mitigates 
this effect, where n=3 technical replicates; (B) Densitometric measurement of ER-stress 
markers from above Western blots images are shown in the bottom, where n=3 technical 
replicates; (C) Quantification of p-IRE1α/t-IREα ratio from Western blots images are 
shown on the right, where n=3 technical replicates; (D) Hcy induced expression mRNA 
levels of GRP78, ATF6, IRE1 α and XBP1 in C2C12 cells (log transformed), where n=3 
technical replicates. The overall difference between the experimental groups was 
determined by one-way or two-way ANOVA, and a Tukey's post hoc analysis was run 
when overall statistically significant difference occurred in group means. Data are shown 
as means.e.m, and *p<0.05 vs. CT and #p<0.05 vs. Hcy.
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Figure 11E-H: High Hcy mediates ER-stress response in muscle in-vivo. (E) Western 
blots analysis showing induced expression of ER-stress markers, such as GRP78, 
ATF6, and p-IRE1α (S724), t-IREα in CBS+Met mice compared to WT mice; whereas 
NaHS treatment mitigates this effect, where mice number (n)=4 in individual group; (F) 
Densitometric quantification of Western blots of above ER-stress markers shown on the 
bottom, where mice number (n)=4 in individual group;  (G) Densitometric analysis of 
pIRE1a/t-IREa ratio from Western blots is shown on the right, where mice number (n)=4 
in individual group; (H) The q-PCR analysis shows that mRNA levels GRP78, ATF6, 
IRE1α, and XBP1 (log-transformed data) were increased in skeletal muscle of CBS+Met 
mice compared to WT mice, where mice number (n)=4 in individual group. The overall 
difference between the experimental groups was determined by one-way or two-way 
ANOVA, and a Tukey's post hoc analysis was run when overall statistically significant 
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difference occurred in group means. Data are shown as means.e.m and *p<0.05 vs. 
WT and #p<0.05 vs. CBS+Met. 
 
Hcy enhanced JNK-phosphorylation. To confirm whether high oxidative and ER-stress 
responses can induce JNK-phosphorylation during HHcy condition, I did Western 
blotting for p-JNK. I found that Hcy significantly induced phosphorylation of JNK in 
comparison with controls; however, I did not find a concomitant reduction in JNK-
phosphorylation via NaHS treatment as shown in Fig. 12A and 12B. To study whether 
JNK-phosphorylation is mediated via ER-stress mechanism(s), I also treated cells with 
tunicamycin (as a known ER-stress inducer). Results revealed that JNK-phosphorylation 
was inhibited by SP600125 (JNK-inhibitor) and induced by tunicamycin (positive control). 
Similar results were observed in phospho-c-Jun levels (a downstream target of JNK). 
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Figure 12. High Hcy induces JNK-phosphorylation in both in-vitro and in-vivo models. (A) 
Western blots data showing Hcy mediated JNK-phosphorylation and induced protein 
expression of p-cJun (S73) in C2C12 cells, where SP600125 was used as a JNK 
inhibitor, and Tunicamice was used as a positive control, where n=3 technical 
replicates; (B) Densitometric measurements of pJNK/t-JNK, and p-cJun/t-cJun ratios 
from Western blots images are shown on the right, where n=3 technical replicates. The 
interaction between multiple groups was determined by one-way or two-way ANOVA, 
including a Tukey's post hoc analysis when significant interaction occurred. Data are 
shown as means.e.m., and *p<0.05 vs. CT and #p<0.05 vs. Hcy; (C) Western blot data 
showing Hcy mediated JNK-phosphorylation and induced protein expression of p-
cJun (S73) in CBS+Met mice compared to WT mice, where mice number (n)=4 in 
individual group; (D) Densitometric measurements of pJNK/t-JNK and p-cJun/t-cJun 
ratios from Western blots images are shown on the right, where mice number (n)=4 in 
individual group. The overall difference between the experimental groups was 
determined by one-way or two-way ANOVA, and a Tukey's post hoc analysis was run 
when overall statistically significant difference occurred in group means. Data are shown 
as means.e.m. and *p<0.05 vs. WT and #p<0.05 vs. CBS+Met.  
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Similarly, I noticed JNK-phosphorylation was induced in skeletal muscle of CBS+Met 
mice compared to WT mice, and interestingly this effect was mitigated via NaHS 
supplementation (Fig. 12C and 12D). 
HHcy induced pro-inflammatory milieu in CBS+Met mice. To identify weather HHcy-
mediated oxidative and ER-stress responses could modulate pro-inflammatory cytokines 
via JNK/cJun axis, I measured levels of these cytokines in plasma samples collected 
from experimental mice. Results showed that IL1α, IL2, IL4, IL6, IL12A, IFN-γ, and TNF-
α, were elevated in CBS+Met in comparison with WT mice (Fig. 13). IL6 and TNF-α 
levels were found to be significantly induced in plasma of CBS+Met as compared to the 
WT mice.  
 
Figure 13. HHcy induced pro-inflammatory milieu in CBS+Met mice in-vivo. The levels of 
inflammatory cytokines such as IL1α, IL2, IL4, IL6, IL12A, IFN-γ, and TNF-α were 
elevated in the plasma of CBS+Met mice in comparison to WT mice. The difference 
between these two groups were determined by unpaired t-test. Data are shown as 
means.e.m. and where mice number (n)=4 in individual group and *p<0.05 vs. WT.  
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Hcy induced cell death involves apoptosis. First, to check the cell viability after Hcy 
treatment, I performed MTT assay. Results showed that Hcy significantly reduced cell 
viability after 24 h and 48 h. Although I did not find significant improvement of cell 
viability in Hcy treated C2C12 cells after 12h and 24 h of NaHS treatment, I noticed 
NaHS improved cell viability significantly after 48 h (Fig. 14A). To identify weather HHcy-
mediated oxidative and ER-stress responses could induce apoptosis via JNK/cJun axis, 
I also did flow cytometry analysis after staining with Annexin V and propidium iodide (PI). 
Similarly, I found Hcy induced apoptosis in C2C12 cells as compared to controls after 48 
h, whereas NaHS treatment substantially mitigated this effect as shown in Fig. 14B and 
14C.  
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Figure 14. NaHS protects against Hcy-induced C2C12 cells death. (A) Hcy treatment 
induces C2C12 cell death after 24 h and 48 h. Cells were treated in 4 experimental 
groups (CT, Hcy, Hcy+NaHS, and NaHS) for 12h, 24h and 48h before being subjected 
to MTT assay, where n=4 technical replicates; (C) Flow cytometry for studying C2C12 
cell death by apoptosis. Representative images of PI and Annexin V expression on 
C2C12 cells surface, where n=4 technical replicates; (D) Quantification of apoptotic cells 
were determined by total percentage of cells which were Annexin V+ and PI+, where n=4 
technical replicates. The overall difference between the experimental groups was 
determined by one-way or two-way ANOVA, and a Tukey's post hoc analysis was run 
when overall statistically significant difference occurred in group means. Data are shown 
as means.e.m., and *p<0.05 vs. CT and #p<0.05 vs. Hcy. 
  
DISCUSSION 
Previously studies reported that HHcy was detrimental to skeletal muscle (20); 
however, molecular mechanisms underlying the detrimental effects of HHcy on muscles 
were not precisely studied. To my knowledge, this is the first study elaborating the 
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mechanistic roles of Hcy during oxidative and ER-stress responses, which can 
potentiate skeletal muscle dysfunction via apoptosis, and inflammation through JNK-
phosphorylation.  
Previous findings demonstrated the effects of HHcy on oxidative stress in cardiac 
microvascular endothelial cells (145), vascular smooth muscle cells (25), and liver tissue 
(26). The results from the present study add to the growing body of evidence that HHcy 
can, in fact, induce pathological changes in muscles via inducing ROS moieties. In this 
study, I also noticed lipid peroxidation andH2O2 levels are equally elevated, and 
GSH/GSSG ratio was reduced by Hcy in C2C12 cells. NaHS treatment was found to 
improve all these conditions (Fig. 10). These results suggest that HHcy in CBS mice due 
to heterozygous CBS deficiency is equally detrimental to skeletal muscle compared to 
WT mice, which may result from higher ROS generation. 
Although oxidative stress has been implicated in many diseases encompassing 
protein misfolding and the disruption of protein folding pathways (28-31), to my 
knowledge this is the first study showing that HHcy could also induce ER-stress 
response in skeletal muscle (Fig. 11). This finding also corroborates the previous 
observations showing that HHcy mediates higher ER-stress responses in endothelial 
cells (150,310,311). A study by Malhotra et al. indicated that antioxidants reduced ER-
stress leading to improved protein secretion (149). Similarly, I also noticed that NaHS 
treatment has a beneficial effect towards mitigating ER-stress response in skeletal 
muscle (Fig. 11).  
JNK pathway is known to control cellular response to harmful extracellular stimuli 
(42,43,312). Whether Hcy-mediated oxidative and ER-stress responses can also induce 
similar effects in skeletal muscle was not studied previously. I found JNK 
phosphorylation was upregulated in C2C12 cells after Hcy treatment, but NaHS could 
not reduce this effect. Whereas, my in-vivo data showed that JNK-phosphorylation was 
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successfully mitigated via NaHS intervention. Since I only studied a single readout (24 
hrs post-HHcy treatment) in in vitro settings, I may have missed an acute Hcy-mediated 
effect on the JNK-phosphorylation. In the in-vivo CBS model, I was able to observe the 
continuous or prolonged effect of the NaHS mediated phospho-JNK status. I noticed the 
apoptosis rate was induced in C2C12 cells after Hcy treatment and it was mitigated by 
the NaHS supplementation (Fig. 14). Furthermore, reduction of apoptosis after NaHS 
treatment confirmed the ability of H2S to alleviate the effects of Hcy. Moreover, this study 
shows that HHcy-mediated upregulation of pro-inflammatory cytokines (TNF-α, IL-1, and 
IL-6) in plasma of CBS+Met mice compared to WT mice (Fig. 13). My results are also in 
agreement with inflammatory bowel disease conditions wherein JNK-upregulation plays 
a vital role (312). Oudi and colleagues reported a similar inflammatory response in acute 
coronary syndrome (ACS) patients, where tHcy, HsCRP, IL-6 and TNFα were 
significantly elevated (313). In addition to these findings, studies from other groups have 
reported that HHcy causes cardiovascular disease via increasing IL-1ra and IL-6 levels 
(314,315). Furthermore, it’s possible that during inflammation immune cells (CD8+ T 
lymphocytes) may cause myocyte degeneration (autoimmune responses) in the muscle 
(14,316).  
HHcy is known to cause hypermethylation of genes (7); however, I did not test 
the possibility of methylation status that may and may not be a factor in HHcy mediated 
apoptosis and inflammatory responses. From this study it is not still confirmed whether 
NaHS mediating its effects via oxidative stress mechanisms or something else and 
whether other antioxidants (like N-acetylcysteine) has similar effects like NaHS. Further 
work is required that might throw light to explore the possible molecular mechanism(s) of 
the actions of H2S and whether it could be developed as a potential therapeutic target for 
treating skeletal muscle dysfunction and related metabolic disorders.
          51 
CHAPTER IV 
 
HYDROGEN SULFIDE IMPROVES POST-ISCHEMIC ANGIOGENIC DEFECT IN THE 
HINDLIMB OF CYSTATHIONINE--SYNTHASE MUTANT MICE (317) 
 
Introduction:   
Homocysteine (Hcy) has been studied extensively in the last 30 years for its 
unique involvement in an increasing number of human diseases (2-4). The Hcy level is 
controlled by two major processes: around 50% of Hcy enters the transsulfuration 
pathway to produce cysteine, and the other half is re-methylated back to methionine via 
the folate 1-carbon cycle (5,6). Normal total plasma Hcy concentration in our body 
ranges from 5-15 μM; however, in a diseased condition, such as in 
hyperhomocysteinemia (HHcy), plasma total Hcy levels are increased (>15 μM) (8). 
HHcy can be classified as moderate (15-30 μM), intermediate (30–100μM) and severe 
(>100 μM) (8). Notably, there are 4 ways people can develop HHcy: (1) consumption of 
a methionine-rich protein diet; (2) vitamin B12/folate deficiency; (3) presence of 
heterozygous/homozygous status for cystathionine-β synthase (CBS+/-/CBS-/-); and (4) 
obstruction of renal clearance (12). Apart from these factors, genetic variants in Hcy 
metabolism enzymes such as 677C>T and 1298A>C in the MTHFR gene can also lead 
to HHcy (14,76-78). There are also several other drivers like age, sex, physical activity, 
alcohol intake, certain medications and different disease conditions 
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(such as type 2-diabetes) that can also modulate the functioning methionine cycle, 
leading to an increased total Hcy concentration in the blood (79). HHcy has been 
associated with severe skeletal muscle dysfunction (7,13-20), but the precise 
mechanism(s) is still unknown. Previous studies found that HHcy causes endothelial cell 
(EC) injury (209), inhibition of EC proliferation (318), reduction of bioavailability of 
vasoregulatory mediators (such as NO and endothelin) (319), and induction of 
oxidative/ER-stress (24,33,320). How HHcy reduces neovascularization in the skeletal 
muscle is not precisely known. 
The growth of new blood vessels from the preexisting vascular network is known 
as angiogenesis. When oxygen supply is low in a tissue or organ, it activates HIF1α, 
which sends a signal to the nearest blood vessel, activating eNOS and producing NO 
needed for vasodilation. VEGF increases permeability and separates pericytes leading 
to the degradation of the basement membrane, thereby activating metalloproteases such 
as MMP-2 and 9 (321). These changes lead to EC proliferation and a concomitant 
migration in order to form new blood vessels (322). In recent years, it has been shown 
that PPAR-γ might be involved in angiogenesis via growth factors and cytokines that in 
turn stimulate migration, proliferation, and survival of these ECs (323). 
PPAR-γ belongs to the nuclear hormone receptor superfamily; when specific 
ligands bind to the ligand-binding domain of PPAR-γ, a conformational change releases 
the bound corepressors (324,325). This allows co-activators like PGC-1α and other 
coactivators to be recruited to the PPAR-γ responsive gene promoters thereby 
promoting the PPAR-γ-mediated transcription (81,326,327). HHcy reduces PPAR-γ 
expression in ECs (148). Studies have shown that PPAR-γ could regulate angiogenesis 
via upregulating VEGF (323) and that can further activate eNOS (328). Although, 
previous works showed that HHcy impaired neoangiogenic growth in muscle via 
reduction of HIF1α and VEGF levels, whether PPAR-γ plays any role in this process had 
         53 
not been studied (46).  
H2S is increasingly being recognized as an important signaling molecule in 
cardiovascular and nervous systems via its ability to neutralize a variety of reactive 
oxygen species (ROS) (51-53), and via increased cellular GSH levels through activation 
of gamma-glutamylcysteine synthetase, and reduction of the disulfide bonds (54-
61,329). CBS and CSE are the main H2S generating enzymes, producing H2S from Hcy 
in the transsulfuration pathway (330). Patients with CBS deficiency tend to produce a 
lesser amount of H2S (63,236), suggesting that these patients are likely more prone to 
oxidative stress-mediated damages due to excessive production of Hcy (54). A study 
revealed that endogenous H2S could induce mRNA and protein expression of PPAR-γ, 
indicating that exogenous H2S supplementation could be employed as a beneficial 
strategy to improve angiogenesis defect in HHcy patients (331). Hence the purpose of 
my study was to answer the following questions: (i) Does HHcy inhibit angiogenesis via 
downregulation of angiogenic signals like HIF1α and VEGF in 21 days of post-FAL 
hindlimb of CBS+/- mice? (ii) Does HHcy inhibit PPAR-γ expression which can further 
downregulate VEGF/eNOS signaling in the post-FAL hindlimb of CBS+/- mice? And 
finally, (iii) Does GYY4137 (an H2S donor) treatment improve angiogenesis via PPAR-
γ/VEGF axis after 21 days of FAL in the hindlimb of experimental CBS+/- mice?  
CBS is one of the key enzymes in the transsulfuration pathway; heterozygous 
CBS deficiency (CBS+/-) has proved to be a useful model for analyzing the effects of mild 
to a severe endogenous elevation in the levels of Hcy (64-71). Hence, in this study, I 
used CBS+/- mouse model to identify the effect(s) of HHcy on angiogenesis in the 
skeletal muscle and evaluate whether exogenous administration of GYY4137 could 
improve this effect(s). Results indicate that H2S could be developed as a potential 
therapeutic agent to treat the neoangiogenic defects in skeletal muscle wherein HHcy is 
linked with a barrage of metabolic dysfunctions. 
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MATERIALS AND METHODS  
Animal maintenance, genotyping and diet protocol. Male WT (C57BL/6J) and 
CBS+/− (B6.129P2-Cbstm1Unc/J 002853) mice were purchased from the Jackson 
Laboratory (Bar Harbor, ME). All animals were ∼8-10 weeks-old and maintained in 
12:12 h light-dark cycle with regular mouse chow diet in the animal facility of the 
University of Louisville. All animal protocols and care were carried out according to 
the guidelines of National Institute of Health (NIH Pub. No. 86–23, revised 1985) and 
were approved by the Institutional Animal Care and Use Committee (IACUC) of the 
University of Louisville, KY, USA.  
After purchasing, mice were cross-bred, yielding around 10 % CBS−/−, 60 % 
CBS+/−, and 25 % CBS+/+. For genotyping, tail samples were collected, and DNA was 
isolated using DNeasy Blood & Tissue Kits (Qiagen, Germantown, MD, USA). Genotypic 
analysis was performed using PCR by targeted disruption of the CBS gene 
(representative images from each group of post-FAL mice are shown in Fig. 15A and 
genotyping in Fig. 15B). CBS+/− heterozygote mice produced two bands (450 and 308 
bp), while wild-type (CBS+/+) mice represented only one band (308bp). Animals were 
divided into 4 experimental groups: (1) Wild-type C57BJ/L6 mice (WT), (2) CBS+/− 
heterozygous mice (CBS) (3) GYY4137-supplemented CBS+/− (CBS+GYY), (4) 
GYY4137-supplemented wild-type mice (WT+GYY). 0.25 mg GYY4137/kg body weight 
of mouse was applied by intraperitoneal injection every day for a total 21 days after 
femoral artery ligation (FAL) surgery, while the WT mice were given 0.9% normal 
saline (vehicle control) (72).  
Femoral artery ligation (FAL). To create a hypoxic condition femoral artery ligation 
(unilateral) was performed under intraperitoneal pentobarbital sodium (50 mg/kg) 
anesthesia (50,51). Briefly, after separation of the femoral artery from the vein and 
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nerve, it was ligated using 6-0 silk suture at proximal and distal places (keeping same 
distance in all animals). I used separate mice groups [WT, CBS, CBS+GYY, and 
WT+GYY] as sham control where I performed the full process of surgery except the 
ligation. The skin was sutured using 6-0 silk thread. After the skin closure, betadine was 
applied. After recovery, laser Doppler blood perfusion was carried out to confirm the 
induction of ischemia.  
Laser-Doppler tissue perfusion imaging and flowmetry. MoorLDI (Moor Instruments) was 
used to measure tissue perfusion intensity and blood flow rates (332). In brief, after 
anesthesia, a part of skin in hind limb was opened and blood flow measurement was 
taken for 2mins keeping same laser pointer in all experimental mice.    
Barium angiograms. To determine angiogenesis, barium sulfate angiography was 
performed in mice (333). In brief, after pentobarbital anesthesia mice were infused with 
barium sulfate (0.1 g/mL) in 50 mM Tris-buffer (pH 5.0) at a constant flow (∼1 ml/min) 
and pressure with a syringe pump through the common carotid artery. Heparin 
(20U/ml) was used along with barium sulfate to visualize the nascent angiogenesis. 
Angiograms were captured using the Carestream whole animal X-ray imaging system 
(Carestream Molecular Imaging, Woodbridge, CT) (334) and the vessel density was 
quantified using VesSeg tool (Institute for Signal Processing, University of Luebeck, 
Lübeck, Germany). 
Reagents and antibodies. All reagents and chemicals were ordered from Sigma–Aldrich 
or available highest grade. 
The antibodies for HIF1α (ab51608), VEGF (ab51745) and eNOS (ab66127) 
were ordered from Abcam (Cambridge, MA, USA). Whereas PPAR-γ (sc-7273), p-eNOS 
Ser1177 (sc-12972), rabbit anti-mouse (sc-358914), mouse anti-rabbit (sc-2357), and 
mouse anti-goat (sc-2354) were from Santa Cruz Biotechnology (Dallas, TX, USA). The 
antibody for GAPDH (MAB374) was from EMD Millipore (Burlington, MA, USA), and 
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used for Western blots analyses as per the manufacturers’ protocols.  
Western blotting. Protein expressions were assessed by Western blots (72). Briefly, at 
the time of sacrifice, gastrocnemius muscle from the ischemic leg of each mouse was 
quickly removed, snap-frozen, and stored at -80 °C until further use. Protein from 
samples was extracted by homogenizing in the ice-cold RIPA buffer (Boston 
BioProducts, Worcester, MA, USA) containing 1 mM Phenylmethylsulfonyl fluoride 
(Sigma, Saint Louis, MO, USA), 1% protease inhibitors cocktail (Sigma, Saint Louis, MO, 
USA) and then sonicated employing the Sonifier 450 (Branson Ultrasonics, Danbury, 
CT, USA) using 3 x 5 sec at setting "3". The homogenates were centrifuged 17,400 × g 
for 20 min at 4 °C, and the supernatants were quickly stored at -80 °C until further use. 
The protein contents were estimated by the Bradford assay. Equal amounts of proteins 
(50 μg) were resolved on SDS-PAGE (8%, 10%, 12%) and then transferred to 
polyvinylidene difluoride (PVDF) membranes. The respective blots were incubated with 
primary and secondary antibodies before visualizing them using the ECL Luminata Forte 
(Millipore, Temecula, CA, USA) in a Bio-Rad ChemiDoc system. The intensities of the 
bands were normalized to the housekeeping GAPDH for all the proteins examined. The 
quantification was performed using Image Lab™ Software (Bio-Rad, Hercules, CA, 
USA).  
Reverse transcription and real-time quantitative PCR. Total RNA was extracted from 
muscle samples using a Trizol method as mentioned in chapter III (306). Then RNA 
quality was determined by NanoDrop ND-1000, and RNA with high purity (260/280~2.00 
and 260/230~2.00) was used for q-PCR analysis. Reverse transcription was performed 
according to the manufacturer’s protocol using high-capacity cDNA RT kit from Applied 
Biosystems (Foster City, CA, USA) for the primer sequences listed in Table 3. For RT-
qPCR, SYBR green-based kit was used to measure the relative expression of each 
mRNA specific primers. Briefly, 3 steps cycling protocol was performed using 20 ng of 
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cDNA template in a 20 μL reaction volume under the following conditions: denaturation 
at 95 °C for 15 min followed by 40 cycles of 94 °C for 15 s, 55 °C for 30 s, and 70 °C for 
34 s in which fluorescence was acquired and detected by Roche LightCycler® 96 Real-
Time PCR System (Roche Diagnostics, Indianapolis, IN, USA). Following RT-qPCR, 
analysis of melt curve was performed to validate the specific generation of the expected 
PCR product. GAPDH was used as an endogenous control (Quanta Biosciences, 
Beverly, MA, USA). 
 
Genes Forward Primers Reverse Primers 
HIF1α 5’- TCAAGTCAGCAACGTGGAAG-3’ 5’- TATCGAGGCTGTGTCGACTG-3’ 
VEGF 5’- CAGGCTGCTGTAACGATGAA-3’ 5’- CAATTTGGCTCCTCCTACCA -3’ 
PPAR-γ 5’- TTTTCAAGGGTGCCAGTTTC-3’ 5’- AATCCTTGGCCCTCTGAGAT-3’ 
NOS3 5’- GACCCTCACCGCTACAACAT-3’ 5’- TCTGGCCTTCTGCTCATTTT -3’ 
   
Table 3. List of primers used for RT-qPCR experiments for chapter V. 
 
Total plasma Homocysteine, hydrogen sulfide, and nitrite measurement. Blood samples 
were collected in tubes containing a 1/10 volume of 3.8% sodium citrate from each 
mouse by cardiac puncture after euthanasia. Then plasma was isolated by centrifugation 
at 2500 × g for 15 mins at 4 °C.  Total plasma Hcy concentrations were measured in 
samples using the homocysteine assay kit (Crystal Chem, IL, USA) as per 
manufacturer’s instructions.  
 Plasma H2S was measured as a previously described method (208). In brief, samples 
were centrifuged at a speed of × 11,000 g for 10 minutes. 100 μl aliquots from the 
plasma were mixed separately with PBS (350 μL) and Zn(O2CCH3)2 (1% W/V, 250 μL) 
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in a micro-centrifuge tube and sealed immediately. Then, N, N-dimethyl-p-
phenylenediamine sulfate (20 mM, 133 μL) in 7.2 M HCl, and FeCl3 30 mM, 133 μL) in 
1.2 M HCl was added to the mixture, sealed and incubated at 37°C for 45 min. After that, 
Trichloroacetic acid solution (10% w/v, 250 μL) was added to the mixture to terminate 
the reaction. After centrifugation (× 2,700 g for 5 mins), 200 μL supernatant was 
transferred to a 96-well plate and the absorbance was measured at 670 nm in a 
spectrophotometer. H2S levels were calculated against a calibration curve of known 
concentrations of NaHS (0.01 - 100 μmol/L).  
 Both nitrite and nitrate from the plasma was measured by a Griess reagent as (301). 
Briefly, equal volume of Griess reagent [0.1 % N-(1-naphthyl) ethylenediamine 
dihydrochloride,1 % sulfanilamide, and 2.5 % phosphoric acid] was added to 100 μL of 
samples and controls [sodium nitrite (NaNo2)] (0.01-100ug). Then samples were 
incubated at 37 °C for 30 min and absorbance was recorded at 542 nm in a Spectra Max 
M2 plate reader. 
Statistics. All values are expressed as mean ± s.e.m. The interaction between groups 
was determined by one-way or two-way ANOVA, including a Tukey's post hoc analysis 
when significant interactions were observed. The threshold for significance was set at 
p<0.05, the total number of mice (n)= 4-5 were subjected to experimentation from each 
group. For statistical analyses, GraphPad Prism (Ver 7, GraphPad Software) was used.  
 
RESULTS 
The phenotypic feature and genotype of WT and CBS+/- mice are depicted in Fig. 
15A and 15B respectively. In this study, I noticed that CBS mice had significantly lower 
body weights in comparison to WT mice; however, I did not see any difference in body 
weights between CBS vs. WT after GYY4137 treatment for 21 days (Fig. 15C). I 
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observed CBS mice had significantly higher levels of plasma tHcy compared to WT 
mice, GYY4137 supplemented CBS mice also had similarly higher plasma tHcy levels as 
that of the CBS mice (Fig. 15D). After 21 days of GYY4137 treatment, I examined the 
plasma H2S concentrations in the experimental mice. Results showed that plasma H2S 
levels were significantly lower in the CBS mice compared to that of the WT mice as 
expected (Fig. 15E). However, after administration of GYY4137 for 21 days plasma H2S 
levels were significantly elevated in both the CBS and WT mice (Fig. 15E). 
 
Figure 15. Phenotypic and genotypic characteristics of experimental mice groups. (A) 
Hindlimb images after 21 days of GYY4137 treatments; (B) Genotyping of experimental 
mice; (C) Body weight measurements of experimental mice, where mice number (n)=4 in 
individual group; (D) tHcy measurements from the plasma of experimental mice, where 
mice number (n)=4 in individual group; (E) H2S measurements from the plasma of 
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experimental mice, where mice number (n)=4 in individual group. The overall difference 
between the experimental groups was determined by one-way or two-way ANOVA, and 
a Tukey's post hoc analysis was run when overall statistically significant difference 
occurred in group means. Data are shown as means.e.m. and statistical difference 
*p<0.05 vs. WT and #p<0.05 vs. CBS.  (tHcy=total homocysteine, FAL=femoral artery 
ligation). 
 
As a marker of a hypoxia induction in post-FAL hindlimb, I measured the HIF1α 
levels by Western blotting. I noticed that HIF1 levels were downregulated in post-FAL 
CBS mice in comparison to WT mice, GYY4137 treatment was found to mitigate this 
effect (Fig. 16A). To confirm mRNA expression of HIF1α, I did qPCR analysis, and it did 
not show any significant decrease in mRNA levels of HIF1α in post-FAL CBS mice 
compared to post-FAL WT (p=0.4824), GYY4137 treatment could not improve the 
mRNA levels in post-FAL CBS mice (p=0.9781) (Fig. 16B). I found that the protein 
expressions of VEGF and PPAR-γ were reduced in post-FAL CBS mice as compared to 
post-FAL WT mice, whereas this effect was improved after GYY4137 administration 
(Fig. 16A). Additionally, in the qPCR analysis, I found mRNA expression of VEGF was 
significantly reduced in the post-FAL CBS mice compared to post-FAL WT mice 
(p=0.0365); however, this effect was not improved upon GYY4137 administration 
(p=0.2139). I did not notice any significant change in the mRNA expression of PPAR-γ 
among the 4 experimental groups (Fig. 16B). I did not find any difference in proteins and 
mRNA levels for HIF1α and VEGF among individual groups of sham mice as shown in 
Fig 16C-D. However, I did notice that the expression of PPAR-γ was reduced in sham 
CBS mice compared to sham WT mice and that GYY4137 supplementation could not 
mitigate this effect. The observed reduction of PPAR-γ mRNA level in sham CBS mice, 
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compared to sham WT mice, was not statistically significant (p=0.7423). Similarly, I did 
not observe any significant improvement in mRNA expression for PPAR-γ in sham CBS 
mice after GYY4237 treatment (p=0.3549) (Fig. 16D). 
 
Figure 16A-B. Effect of GYY4137 on the improvement of angiogenic markers in skeletal 
muscle of post-FAL mice. (A) Western blot analysis is showing protein expressions: 
HIF1-α, VEGF, and PPAR-γ in the top panel and densitometric analysis of Western blot 
images are shown in the bottom panel, where mice number (n)=4 in individual group; (B) 
mRNA expression for HIF1-α, VEGF, and PPAR-γ (log transformed) in skeletal muscle 
of post-FAL mice, where mice number (n)=4 in individual group. The overall difference 
between the experimental groups was determined by one-way or two-way ANOVA, and 
a Tukey's post hoc analysis was run when overall statistically significant difference 
occurred in group means. Data are shown as means.e.m. and statistical difference 
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*p<0.05 vs. WT and #p<0.05 vs. CBS (FAL=femoral artery ligation).
 
Figure 16C-D. Effect of GYY4137 on angiogenic markers in skeletal muscle in sham 
mice. (C) Western blot analysis is showing protein expressions: HIF1-α, VEGF, and 
PPAR-γ in the top panel and densitometric analysis of Western blot images are shown in 
the bottom panel, where mice number (n)=4 in individual group; (D) mRNA expression 
for HIF1-α, VEGF, and PPAR-γ (log transformed), where mice number (n)=4 in individual 
group. The overall difference between the experimental groups was determined by one-
way or two-way ANOVA, and a Tukey's post hoc analysis was run when overall 
statistically significant difference occurred in group means. Data are shown as 
means.e.m., statistical difference *p<0.05 vs. WT and #p<0.05 vs. CBS. 
 
Finally, I measured the vessel density employing barium sulfate angiography 
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after 21 days of FAL surgery. It was noticed that total collateral vessel numbers were 
significantly less in the post-FAL CBS mice in comparison to post-FAL WT mice, this 
effect was further significantly improved upon GYY4137 treatment (Fig. 17A-B). Besides, 
blood flow in the hindlimb after 21 days of FAL was reduced considerably in CBS mice 
compared to WT mice, and it was improved by GYY4137 treatment as seen in Fig. 17C-
D. Although I did not notice any difference in the mRNA expression levels of NOS3, I 
observed that the p-eNOS levels were reduced in the post-FAL CBS mice as compared 
to post-FAL WT mice, interestingly, this effect was improved via GYY4137 treatment 
(Fig. 17E). The changes in the plasma nitrite levels in experimental mice were also 
monitored as the marker of nitric oxide (NO) production. Although not statistically 
significant, my findings revealed a reduction of plasma nitrite levels in post-FAL CBS 
mice as compared to post-FAL WT mice (p=0.1050), and similarly, I noticed a trend of 
improvement of this effect with the GYY4137 administration (p=0.2923) (Fig. 17F). 
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Figure 17A-D.  GYY4137 supplementation improves angiogenesis in the hindlimb 
muscle after 21 days of FAL in CBS+/- mice. (A) Barium angiogram images showing 
vascular density in the hindlimb of skeletal muscle; (B) Quantitation of collateral vessel 
numbers in hindlimb post FAL mice, where mice number (n)=4 in individual group; (C) 
Blood flow rate measurements in hindlimb post FAL mice, where mice number (n)=4 in 
individual group; (D) Laser-Doppler perfusion imaging showing the intensity of limb 
perfusion 21 days post FAL mice. The overall difference between the experimental 
groups was determined by one-way or two-way ANOVA, and a Tukey's post hoc 
analysis was run when overall statistically significant difference occurred in group 
means. Data are shown as means.e.m. and statistical difference *p<0.05 vs. WT and 
#p<0.05 vs. CBS. (FAL=femoral artery ligation). 
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Figure 17E-F. Effect of GYY4137 supplementation on eNOS-phosphorylation and 
plasma nitrite levels in experimental mice. (E) Western blot analysis of protein 
expressions: p-eNOS and eNOS in the top panel and densitometric analysis of p-
eNOS/eNOS ratio from Western blot images are shown in the right panel, and mRNA 
expression of NOS3 is shown in bottom panel, where mice number (n)=4 in individual 
group; (F) Nitrite+Nitate levels in plasma of post-FAL mice measured by Griess assay, 
where mice number (n)=4 in individual group; The overall difference between the 
experimental groups was determined by one-way or two-way ANOVA, and a Tukey's 
post hoc analysis was run when overall statistically significant difference occurred in 
group means. Data are shown as means.e.m. and statistical difference *p<0.05 vs. WT 
and #p<0.05 vs. CBS. (FAL=femoral artery ligation) 
 
DISCUSSION 
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Earlier studies also showed that HHcy has a profound inhibitory effect on EC 
proliferation and their migration (269,270,335-337). In the present study, I examined 
whether HHcy condition could impair angiogenesis in-vivo during a chronic ischemic 
insult. Although there are many in-vivo models available to study angiogenesis, either by 
passing a flexible wire or by applying a laser or an electrical current, none of these are 
relevant to the clinical setting (338-340). In this study, I used the femoral artery ligation 
(FAL) model by employing a genetically engineered mouse model (CBS+/-) mimicking 
HHcy conditions as seen in HHcy patients with CBS mutation to study the post-ischemic 
angiogenesis phenomenon during HHcy.  My results showed that HHcy is associated 
with defective angiogenesis, and exogenous H2S supplementation has a protective role 
in mitigating this effect.  
Angiogenesis is a natural process during chronic regional ischemia, which 
requires EC proliferation, migration, differentiation, and survival to form new blood 
vessels in order to compensate for the hypoxic environment (341). VEGF is a 
prototypical angiogenic cytokine that plays a vital role in this process and has been 
widely studied (342-344). A previous report involving hindlimb ischemia in CBS+/− mice 
showed no difference in VEGF levels 7 days of post-ischemia (345). However, they did 
notice a significant reduction in capillary density in the CBS mice compared to WT mice 
after 21 days of ischemia (345). Interestingly, my results demonstrate a significant 
decrease in PPAR- and VEGF expression after 21 days of FAL, suggesting that lower 
expressions of post-ischemic PPAR- may be responsible for delayed induction of VEGF 
in CBS mice compared to that of WT mice (323). I noticed that the exogenous 
administration of GYY4137 could improve blood flow and collateral vessel density in 
skeletal muscle of CBS+/- mice (Fig. 17C). 
H2S has been studied extensively for its positive effects in the cardiovascular 
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system, demonstrating profound vasodilatation, vascular protection, homeostatic 
regulation of blood pressure and many others (54,57-59,61). A previous study using 
chicken chorioallantoic membrane model revealed that H2S increased the length and 
complexity of the vascular network (270). Likewise, in this study, I noticed that 
exogenous supplementation of GYY4137 could improve collateral vessel density after 21 
days of FAL in the CBS+/- mice. Similar to this study, Moore and colleagues were able to 
show that intraperitoneal administration of NaHS induced neovascularization in an in-
vivo mouse model using a Matrigel plug assay (269). A previous report showed that 
genetic deletion/silencing of CSE (another H2S-producing enzyme) in the endothelium 
reduced migration and sprouting of ECs in-vitro, wherein VEGF played a critical 
mediator (270). In the present study, I observed that PPAR-γ and VEGF expressions 
were significantly downregulated in CBS mice compared to WT mice. I also 
demonstrated that these effects were mitigated via GYY4137 administration. This 
suggests that most likely VEGF is regulated via the PPAR-γ dependent pathway, further 
corroborating Biscetti, et al.’s findings wherein they clearly showed that activation of 
PPAR-γ led to endothelial tube formation and induction of VEGF in ECs (323). Similarly, 
other investigators revealed that inhibiting PDE activity by H2S induces PPAR-γ protein 
and mRNA expressions (331). 
NO is also an endogenous gasotransmitter that, like H2S, is involved in 
vasorelaxation and stimulation of angiogenesis (346,347). HHcy was also found to 
quench NO (a vasodilator) by the formation of peroxynitrite anion (ONOO-) and 
uncoupling of eNOS, further reducing the bioavailability of NO (348-350). Similarly, I 
noticed nitrite levels and phosphorylation of eNOS were found to be reduced in CBS 
mice in comparison to WT mice. eNOS is known to produce NO during angiogenesis via 
VEGF axis (328); thus, it appears that impaired angiogenesis in HHcy could be due to 
the reduction of NO bioavailability. In this work, I demonstrated that nitrite levels and 
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eNOS activation were reduced in the CBS+/- mice compared to WT mice, and their levels 
could be recovered via GYY4137 treatment. These findings are also highly consistent 
with previous reports where H2S was shown to stimulate Akt in endothelial cells, leading 
to the induction of eNOS through phosphorylation of Ser1177 (activation site) and 
parallel dephosphorylation of Thr495 (inhibitory site) (351,352).  
 In conclusion, my work embodies the pro-angiogenic role of the H2S molecule 
during HHcy condition. I opine that additional pathways might be at work during 
angiogenesis (97); however, further investigation needs to be undertaken involving 
similar but not identical scenarios wherein muscle myopathy is the outcome of metabolic 
abnormalities. In brief, H2S does hold potential ramifications towards developing it as a 
clinically relevant therapeutic option for chronic conditions that are implicated in a host of 
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CHAPTER V 
HYDROGEN SULFIDE MITIGATES HHCY-MEDIATED SKELETAL MUSCLE 
ATROPHY VIA JNK/FOXO1 AXIS 
 
Introduction 
Homocysteine (Hcy), a sulfur-containing non-protein amino acid is generated via one-
carbon metabolism in the methionine cycle. Dietary methionine is first converted to S-
adenosyl methionine (SAM) and then to S-adenosyl homocysteine (SAH) in methionine 
cycle. SAH is further converted to Hcy which is remethylated to methionine via folate 
cycle and the cycle continues (353). Under conditions of low cysteine or saturation of 
Hcy remethylation, Hcy is further metabolized by the transsulfuration pathway to 
cysteine (2). In the rate-limiting step of the transsulfuration pathway, Hcy is first 
converted to cystathionine through cystathionine β-synthase (CBS) where Vitamin B6 
(pyridoxine) is an essential co-factor (7). Cystathionine is further transformed to cysteine 
by cystathionine γ-lyase (CSE), which further generate GSH. The normal range of 
plasma Hcy levels for young adults (0-30 years) is 4.6 - 8.1 µM and for older adults (30 
years and above) is 4 -15 µM (354). In healthy individuals, the generation and 
elimination of Hcy remain at equilibrium. However, during hyperhomocysteinemia 
(HHcy), the plasma Hcy levels tend to increase (moderate HHcy: 15-30 µM, intermediate 
HHcy: 30–100 µM, and severe HHcy: >100 µM) (7,355). Mutations in the CBS gene 
causes Hcy accumulation in the blood circulation due to disruption of the transsulfuration 
pathway (356).  
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Skeletal muscular atrophy is a pathophysiological condition that arises due to 
HHcy (357). It causes loss of skeletal muscle mass, leading to muscle weakness, 
inactivity, and increased mortality (5,15,20,21,46,66,82). The molecular mechanism 
attributed to muscle atrophy is the upregulation of ubiquitin ligases like RING-finger 
protein-1 (MURF-1) and muscle atrophy F-box (MAFBx), also known as Atrogin-1, which 
initiates the degradation of muscular proteins and eventually cell death and muscle mass 
reduction (358,359). Indeed, several E3 ubiquitin ligases, such as muscle MuRF1, 
MAFBx, Nedd4.1, TRAF6, and MUSA1, have been identified which mediate degradation 
of both thick and thin filaments during skeletal muscle atrophy (214,215). Therefore, 
identification of the precise molecular mechanism(s) as to how these E3 ubiquitin 
ligases are regulated during HHcy is essential to devise future preventive strategies.  
Forkhead Box (FOX) proteins are a group of transcription factors with a 
conserved DNA binding domain and are responsible for regulating a number of E3-
ubiquitin ligases upon a variety of cellular stress responses (216-219). Previous studies 
showed that growth factor-activated protein kinase B (Akt) and stress-activated c-Jun N-
terminal kinase (JNK) have opposing effects on FOX class O (FOXO) (common in 
mammals): Akt inhibits FOXO activity via preventing its nuclear localization, whereas 
JNK increases FOXO activity by promoting its import in the nucleus (216,220-223). 
FOXO1 and 3 are widely expressed across all tissues, FOXO4 is primarily expressed in 
muscle and kidney tissues, and FOXO6 is expressed in developing brain and liver 
tissues (360). Post-translational modifications of FOXOs determine its regulation and 
therefore, its cellular localization (216). FOXO1 has been shown to be the primary 
transcription factor regulating MuRF1 and Atrogin-1, these two proteins were reported to 
be highly upregulated during skeletal muscular atrophy (224).  
CBS and CSE are the vital enzymes generating H2S from Hcy via the 
transsulfuration pathway (330). H2S is increasingly being recognized as an important 
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signaling molecule in the cardiovascular and nervous systems because of its ability to 
neutralize a variety of ROS moieties (63,236,329).  In fact, patients with a dysregulated 
Hcy metabolism due to CBS deficiency are likely to be more prone to oxidative stress-
mediated damages (361,362). Hence, the purpose of this study was to analyze whether 
Hcy instigates muscle atrophy via upregulation of E3 ubiquitin ligases like MURF-1 and 
Atrogin-1 through JNK/FOXO1 axis and H2S attenuates these effects. My results 
suggest that HHcy can induce muscle atrophy via upregulation of Atrogin-1 and MuRF1, 
whereas H2S could be used as a therapeutic option to restore physiological homeostasis 
in skeletal muscle during HHcy condition.  
 
Materials and methods 
Animal maintenance and diet protocol. Male wild-type (WT, C57BL/6J) and 
CBS+/− (B6.129P2-Cbstm1Unc/J 002853) mice were purchased from the Jackson 
Laboratory (Bar Harbor, ME, USA) (71). All animals were ∼8-12 weeks-old and 
maintained in 12:12 h light–dark cycle with regular mouse chow diet in the animal 
facility of the University of Louisville. All animal protocols and care were carried out 
according to the guidelines of National Institute of Health (NIH Pub. No. 86–23, 
revised 1985) and were approved by the Institutional Animal Care and Use Committee 
(IACUC) of the University of Louisville (KY, USA). Animals were divided into 4 
experimental groups: (1) Wild-type C57BJ/L6 mice (WT), (2) CBS+/−heterozygous mice 
fed with methionine (CBS+Met) (3) NaHS-supplemented wild-type mice (WT+NaHS), 
and (4) NaHS-supplemented CBS+/−+Met (CBS+Met+NaHS). Mice were treated with 
NaHS for 8 weeks (30μM/kg/day, I.P.) and fed with a methionine-enriched and low-
folate, low-Vitamin B6, low-B12 diet (Cat. No. TD 97345; Harlan Teklad, Madison, WI, 
USA) (301-304), while the WT mice were given 0.9% normal saline (vehicle control) 
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and fed with normal chow (Purina Farmer's Exchange, Framingham, MA, USA).  
Body weights and physical activity monitoring and tissue collection. Body weights 
were measured at 0 week, 4 weeks and after 8 weeks intervals during NaHS 
treatment (Table 4, Appendix I). Further, the animals were routinely inspected for 
discomfort, body posture, skin integrity (injury), and fur appearance to monitor their 
physical activity. At the end of the experiment, animals were euthanized by using 2X 
tribromoethanol (TBE), and both blood and muscle samples were collected for further 
analysis. 
Genotype analysis of the heterozygous CBS+/− mouse. After purchasing, mice were 
cross-bred, yielding around 10 % CBS−/−, 60 % CBS+/−, and 25 % CBS+/+. For 
genotyping, tail samples were collected, and genotypic analysis was performed using 
PCR by targeted disruption of the CBS gene at loci, as shown in Fig. 18A. The PCR 
products were run on 1.2 % agarose gel (prepared in TAE buffer, pH 8.4) in the 
presence of ethidium bromide and the images recorded in a gel documentation system 
(305). CBS+/− heterozygote gene-positive mice produced two bands (450 and 308 bp), 
while CBS+/+ mice represented only one band (308 bp). 
Cell culture and treatments. C2C12 cells (immortalized mouse myoblast cell line, ATCC) 
were cultured in Corning® T-75 flasks in ATCC-formulated DMEM supplemented with 
10% Fetal Bovine Serum (FBS), 0.1% penicillin and streptomycin (P/S) at 37 °C with 5% 
CO2. The C2C12 cells were grown to 80% confluence and were plated for 4 different 
experimental groups: Group 1: CT (PBS as vehicle control); Group 2: Hcy (500µM); 
Group 3: Hcy+NaHS (250 µM) and Group 4: NaHS. In this study, we used 1mM Hcy and 
250µM NaHS concentrations for the individual treatments (20,246). A stock solution of 
Hcy, NaHS were prepared by directly dissolving in basal DMEM medium (serum-free 
media). Following 24 h of treatment as mentioned earlier, cells were processed for 
further biochemical analysis.  
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Reagents and antibodies. Dulbecco's Modified Eagle's Medium (DMEM), fetal bovine 
serum (FBS) were purchased from American Type Culture Collection (Manassas, VA, 
USA) and trypsin EDTA was from VWR (Radnor, PA, USA). ECL reagent and 
polyvinylidenedifluoride (PVDF) membrane were from Bio-Rad (Hercules, CA, USA). All 
other reagents and chemicals were ordered from Sigma–Aldrich or available highest 
grade. 
Primary antibodies for Western blot analysis: rabbit anti-FOXO1A (1:1000, 
Abcam, Cat # ab12161), rabbit anti-p-FOXO1A (Thr24) (1:1000, Millipore, Cat #2599), 
mouse anti-GAPDH (1:10000, Millipore, Cat # MAB374). Atrogin-1 (1:1000, Abcam Cat 
# ab92281), myosin heavy chain-I (MHC-I) (1:1000, Abcam Cat # ab11083), MuRF-1 
(1:1000, Abcam Cat # ab172479) and Laminin (1:1000, Abcam Cat # ab11575). 
Secondary antibodies for Western Blot Analysis: mouse anti-rabbit (1:2000), rabbit anti-
mouse (1:2000) were ordered from Santa Cruz Biotechnology (Dallas, TX, USA). Alexa 
Fluor 488 donkey anti-mouse (Cat # R37114), Alexa Fluor 488 donkey anti-rabbit IgG 
(H+L) (1:1000, Cat # A21206), Alexa Fluor 546 donkey anti-mouse IgG (H+L) (1:1000, 
Cat # A10036), Alexa Fluor 546 donkey anti-rabbit IgG (H+L) (1:1000, Cat # A10040) 
were ordered from Invitrogen (Eugene, OR, USA) 
Immunocytochemistry (ICC). For ICC, C2C12 cells were grown in chamber slides (Lab-
Tek II) and treated as mentioned above. After 24 h of treatment, cells were washed 2 
times with 1X phosphate buffer saline (PBS) and fixed with 4% paraformaldehyde (PFA) 
diluted in 1X PBS for 10 minutes at room temperature. The cells were permeabilized and 
blocked at the same time with a solution of 2 % bovine serum albumin (BSA) and 0.5 % 
Triton X-100 in 1X PBS for 30 minutes at room temperature. The cells incubated with 
primary antibodies diluted in 0.1% BSA and 0.5 % Triton X-100 in 1X PBS at the 
concentrations as mentioned above and kept for overnight at 40C. The next day the cells 
were washed 3 times with 1X PBS and then incubated with secondary antibody using 
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the concentrations as mentioned above for 1 h at room temperature. After washing the 
cells 5 times with 1X PBS after secondary antibody incubation, they were mounted with 
mounting media containing DAPI (Vectashield Cat # H-1200) and viewed under the 
confocal microscope (Olympus FluoView1000, Pittsburgh, PA, USA). 
Immunohistochemistry (IHC). For IHC, I used cryo-tissue sections of the gastrocnemius 
muscle (7 µm) which were labeled for immunofluorescence following the standard 
protocol. Briefly, first, the tissue sections were fixed in 4% paraformaldehyde and 
permeabilized with 0.25% Triton X-100 in PBS. Then, the sections were incubated 
overnight in primary antibodies at 4 °C, and after that, secondary antibodies labeled with 
either Alexa Fluor-488 or 594 (Invitrogen) appropriate to the primary antibody species 
were applied. Sections were cover-slipped with ProLong™ Gold Antifade Mountant. 
Stained images were visualized and analyzed for fluorescence intensity under an 
EVOS™ FL Auto Imaging System (Thermo Fisher Scientific, Waltham, MA, USA) using 
an appropriate filter. To study the cross-sectional area in the gastrocnemius muscle from 
each group, I analyzed 30-40 fields/mouse. 
Western blot analysis. First, the cells or tissues were mixed with cold RIPA lysis buffer 
with protease inhibitor cocktail, phenylmethylsulfonyl fluoride (PMSF) and phosphatase 
inhibitor (sodium orthovanadate) and then sonicated employing the Sonifier 450 
(Branson Ultrasonics, Danbury, CT, USA) using 3 x 5 sec at setting "3". After that the 
suspensions were centrifugated at 17,400 x g for 20 minutes at 40C. The supernatants 
were collected in fresh tubes and were stored at -800C until further use. Protein 
concentration was determined using Bradford assay to ensure that the proteins were 
loaded in equal concentrations. Protein lysates were subjected to 8-12% sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) in a tris-glycine-SDS buffer for 
proper protein separation and transferred on a polyvinylidene difluoride (PVDF) 
membrane electrophoretically overnight at 40C. The membrane was first blocked using 
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5% milk in 1X tris-buffer saline and Tween 20 (TBS-T) for 1 hr at 40C and then incubated 
with the primary antibodies at the concentrations as mentioned above for overnight at 
40C. After primary antibody incubation, the membranes were washed 3 times with 1X 
TBS-T followed by incubation with secondary antibody conjugated with HRP for 1 hr at 
room temperature. Membranes were again washed 3 times with TBS-T, then developed 
using ECL Luminata Forte reagent (Millipore, Temecula, CA, USA) and imaged using a 
Chemidoc (Bio-Rad, Hercules, California, USA). Band intensity was determined using 
densitometry analysis using Image Lab™ Software (Bio-Rad, Hercules, CA, USA). 
Total Homocysteine measurement. The total tHcy levels were measured from plasma of 
experimental mice using homocysteine assay kit (Crystal Chem, IL, USA) as per 
manufacturer’s instructions.   
Muscle fatigability tests. Muscle fatigability test was developed from recommendations 
listed in the Resource Book for the Design of Animal Exercise Protocols by the American 
Physiological Society (APS) with minor modifications. First, one mouse at a time was 
allowed to swim for 10 mins across 4 different days for acclimatization to the 
environment. I used a swimming tub with water temperature usually between 32-
36ºC.  The depth of water was maintained at a minimum of 30cm so that mice couldn’t 
touch the bottom with 10–15cm distance left from the top to prevent animals from 
climbing or jumping out. On the final day, each mouse was placed in the water to swim 
to check their maximum swimming capacity (Table 5, Appendix I). To monitor their live 
motion, I used Clever Systems (Reston, VA, USA) in the previously discussed method 
(46). If the mice discontinue swimming for 2 secs, they were gently nudged to promote 
their movement, and if they were drowning in the water, then they were immediately 
taken out as per protocol.  
To determine muscle grip strength of experimental mice, I used Rotarod 
instrument (San Diego Instruments, San Diego, CA, USA) and Grip strength test meter 
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(Bioseb, Pinellas Park, FL, USA) (364,365). Briefly, Rotarod performance was done by 
placing them on the rotarod and allowing them to run at a constant low speed (12 RPM) 
for 5 mins across 4 different days (acclimatization steps). Following acclimatization, on 
the final day mice were placed on the rotarod (12 RPM) and allow to run until they fall off 
from the apparatus (time was recorded) (Table 5, Appendix I). The grip strength of both 
forelimbs and hindlimbs were measured by using a grip strength meter. Each mouse 
was held by the base of the tail and placed in front of the grasping grid. Once the mouse 
grasped the grid, it was slowly pulled back until the pulling force overcame the mouse's 
grip strength. This process was repeated 5 times for each mouse with 15 mins gap 
between each repeat and all measurements of grip strength/body weights were recorded 
(Table 5, Appendix I).   
Statistical analysis. All values were expressed as mean ± s.e.m. One-way or two-way 
ANOVA was conducted for the statistical analyses for the different treatment groups 
using GraphPad Prism (Ver. 7) software. For all in-vivo experiments mice number (n)= 4-
5, in each group, and for all exercise capacity test, (n)=9-11 mice were used in each 
group. The significance threshold was set at p<0.05. A minimum of 3 technical replicates 
were conducted for each protein expression analysis and ICC experiment. 
 
Results 
HHcy causes skeletal muscle atrophy in CBS+Met mice. In this study, I noticed 
CBS+Met mice had significantly low body weights most likely because of excessive 
muscle wasting in comparison to WT mice (Fig. 18A and 18B). Although I didn’t observe 
any changes in tibial length between each group of experimental mice, gastrocnemius 
and quadriceps muscles weights were significantly reduced in CBS+Met compared to 
WT mice (Fig. 18C and 18D). Although not significant, I did notice a reduction of tibialis 
anterior (TA), extensor digitorium longus (EDL) and soleus muscles weights in CBS+Met 
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mice compared to WT mice. After administration of NaHS for 8 weeks, I noticed an 
improvement in overall body weights and muscle mass as shown in Fig. 18C and 18E. I 
also noticed tHcy levels in plasma were significantly increased in CBS+Met than WT 
mice and was similar in NaHS treated CBS+Met mice (Fig. 18F).  
 
Figure 18: Genotypic and phenotypic characteristics of experimental mice groups. (A) 
Genotyping of CBS+/- and WT mice; (B) morphological difference of skeletal muscle in 
hindlimbs between CBS+Met and WT mice; (C) difference in various muscle weights 
such as gastrocnemius (gastroc), quadriceps (Quad), tibialis anterior (TA), extensor 
digitorium longus (EDL) and soleus, where mice number (n)=4 in individual group; (D) 
Tibia length measurements, where mice number (n)=4 in individual group; (E) Body 
weight measurements, where mice number (n)=4 in individual group; (F) total 
homocysteine (tHcy) measurements, where mice number (n)=4 in individual group. The 
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overall difference between the experimental groups was determined by one-way or two-
way ANOVA, and a Tukey's post hoc analysis was run when overall statistically 
significant difference occurred in group means. Data are shown as means.e.m. and 
statistical difference *p<0.05 vs. WT and #p<0.05 vs. CBS+Met.    
 
NaHS treatment improves muscle fatigability in CBS+Met mice. To measure HHcy effect 
on muscle fatigability, I performed swimming capacity test for all experimental groups.  I 
noticed that CBS+Met mice moved less distance and spent less time in swimming, 
whereas NaHS supplementation improved their capacities significantly (Fig. 19A and 
19B). Similar findings were also observed for the muscle grip strength test as shown by 
less latency to fall from rotarod and grip strength/BW in CBS+Met as compared to WT 
mice. After 8 weeks of NaHS administration, these effects were substantially improved in 
CBS+Met mice (Fig. 19C and 19D).  
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Figure 19: NaHS treatment improves muscle fatigability in CBS+Met mice compared to 
WT mice. (A) Measurements of muscle fatigability was done by swimming test, in the left 
side shows total distance moved and on the right side shows total time spent during the 
swimming performance test; (B) Images captured during live recording of swim test 
(top), representative animal tracings were shown after motion performance in swimming 
test for each group (bottom); (C) Images showing results of grip strength using rotarod 
performance test (left) and grip strength test (right). (D) Images captured in rotarod (top) 
and Bioseb grip strength meter (bottom) during grip strength test. The overall difference 
between the experimental groups was determined by one-way or two-way ANOVA, and 
a Tukey's post hoc analysis was run when overall statistically significant difference 
occurred in group means. Data are shown as means.e.m. and mice number (n)=9 mice 
and *p<0.05 vs. WT and #p<0.05 vs. CBS+Met. 
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HHcy induced morphological changes in skeletal muscle in-vivo. To understand the 
effect of HHcy on morphological changes in the muscle fibers, I analyzed the cross-
sectional areas (CSAs) by laminin staining. Results of the staining showed a significant 
reduction of CSAs in gastrocnemius muscle fibers isolated from CBS+Met in comparison 
to WT mice (Figure 20A and 20B). Although not statistically significant, I observed an 
improvement of CSAs of skeletal muscle fibers in CBS+Met mice after NaHS treatment 
for 8 weeks.    
 
Figure 20: HHcy reduces cross-sectional areas (CSAs) of skeletal muscle fibers in 
CBS+Met mice compared to WT mice. (A) Laminin staining showing cross-sectional 
areas (CSAs) measurements are low in GA muscle of CBS+Met mice compared to WT 
mice (Bar=200μm); (B) Quantification of CSAs form laminin staining images are shown 
on the right. To study the CSAs of the gastrocnemius muscle fiber from each group, I 
analyzed 30-40 fields/mouse. Representative image from each group of mice is shown 
here. The overall difference between the experimental groups was determined by one-
way ANOVA, and a Tukey's post hoc analysis was run when overall statistically 
significant difference occurred in group means. Data are shown as means.e.m. and 
mice number (n)=4 and *p<0.05 vs. WT. 
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To check whether HHcy induces fibrosis in skeletal muscle fibers, I performed 
H&E and Masson trichrome staining in muscle CSAs of gastrocneous muscle. Results 
revealed a higher level of fibrosis and collagen deposition in muscle CSAs derived from 
CBS+Met as compared to WT mice. Interestingly, treatment with NaHS for 8 weeks was 
found to alleviate these effects in CBS+Met mice (Fig 21A-21C).  
 
Figure 21: HHcy-induced fibrosis and collagen deposition in skeletal muscle in-vivo. (D) 
H&E staining in cross sectional areas of gastrocnemius muscle showing morphological 
differences of muscle fibers between CBS+Met and WT mice, images are taken using 
EVOS® FL Auto Cell Imaging System where mice number (n)=4. (Bar=400μm), 
Representative areas from H&E staining images are zoomed in to show more clear view; 
(E) Quantification of regenerated muscle fibers as quantified by centrally located nuclei 
from H&E staining images; (F) Masson’s Trichrome staining in cross sectional areas 
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(CSAs) of gastrocnemius muscle showing blue color stain (white arrowheads) as 
collagen deposition in the muscle of CBS+Met mice compared to WT mice. Images are 
taken using EVOS® FL Auto Cell Imaging System where mice number (n)=4-5. 
(Bar=400μm); (G) Quantification of collagen deposition as quantified by blue color stain 
from Masson’s Trichrome staining images. The overall difference between the 
experimental groups was determined by one-way ANOVA, and a Tukey's post hoc 
analysis was run when overall statistically significant difference occurred in group 
means. Data are shown as means.e.m. and mice number (n)=4-5 and *p<0.05 vs. WT 
and #p<0.05 vs. CBS+Met. 
 
Effect of Hcy on Akt-phophorylation, and subcellular localization of FOXO1. To study the 
effect of HHcy on Akt-phosphorylation, I did Western blots analysis; the results showed 
that Hcy treatment significantly reduced Akt-phosphorylation in C2C12 cells as 
compared to vehicle controls, whereas this effect was successfully mitigated via NaHS 
administration (Fig. 22A).  
As I noticed Akt-phophorylation is downregulated and JNK-phosphorylation is 
upregulated after Hcy treatment in C2C12 cells (Figure 22A and 12),  I tested the 
subcellular localization of FOXO1 using ICC analysis. My confocal images showed that 
p-FOXO1 is primarily localized in the nucleus and FOXO1 is primarily expressed in the 
cytoplasm in the cells across all the treatment groups (Fig. 22B). However, I observed 
that the pFOXO1/FOXO1 ratio is high for Hcy treated C2C12 cells compared to controls 
and this effect was reversed via NaHS supplementation (Fig. 22B). 
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Figure 22: Hcy attenuates Akt-phosphorylation and induced nuclear localization of p-
FOXO1 in C2C12 cells. (A) Western blots analysis showing Hcy treatment reduced Akt- 
phosphorylation, whereas NaHS treatment mitigates this effect. Densitometric 
measurement of Akt-phosphorylation from above Western blots image is shown on the 
right, where n=3 technical replicates; (B) Representative images showing intracellular 
localization of p-FOXO1 and FOXO1 in the left. The p-FOXO1/FOXO1 ratio based on 
fluorescent intensity from ICC images are shown on the right, where n=3 technical 
replicates. Cells were observed and imaged under the confocal microscope at 100X 
magnification. Quantification of fluorescent intensity were shown on the right. The overall 
difference between the experimental groups was determined by one-way ANOVA, and a 
Tukey's post hoc analysis was run when overall statistically significant difference 
occurred in group means. Data are shown as means.e.m., and *p<0.05 vs. CT and 
#p<0.05 vs. Hcy. 
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Hcy enhanced Atrogin-1 and MuRF-1 expression in the skeletal muscle. I noticed the 
expression of Atrogin-1 and MuRF-1 were higher in Hcy treated C2C12 cells in 
comparison to vehicle controls, and this effect was attenuated by NaHS treatment (Fig. 
23A). Similar findings were observed in muscle collected from experimental mice (Fig. 
23B). In addition, IHC experiments confirmed higher MuRF-1 and reduced myosin heavy 
chain type-I (MHC-I) expression in skeletal muscle of CBS+Met mice as compared to 
WT mice, and this effect was alleviated by NaHS treatment (Fig. 24A-C). The Western 
blot results also confirmed a similar association as seen in IHC staining (Figure 24D and 
E). 
 
Figure 23. Hcy enhanced Atrogin-1 and MuRF-1 expressions in the skeletal muscle. (A) 
Western blots data showing expression of Atrogin-1 and MuRF-1 were elevated in 
C2C12 cells after Hcy treatment compared to controls. Densitometric measurements of 
Atrogin-1 and MuRF-1 expression from above Western blots images are shown on the 
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bottom, where n=3 technical replicates. Data are shown as means.e.m., where n=3-4 
biological replicates and *p<0.05 vs. CT and #p<0.05 vs. Hcy. (B) Western blots data 
showing expression of Atrogin-1 and MuRF-1 were elevated in the muscle of CBS+Met 
mice compared to WT mice. (H) Densitometric measurement of Atrogin-1 and MuRF-1 
expression from above Western blots images is shown on the bottom, and where mice 
number (n)=4. The overall difference between the experimental groups was determined 
by one-way or two-way ANOVA, and a Tukey's post hoc analysis was run when overall 
statistically significant difference occurred in group means. Data are shown as 
means.e.m. and *p<0.05 vs. WT and #p<0.05 vs. CBS+Met.  
 
 
Figure 24. High Hcy mediates elevated expression of MuRF1 and degradation of its 
targets protein MHC-1 in skeletal muscle of CBS mice compared of WT mice. (A) 
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Immunohistochemistry analysis showing representative images of elevated expression 
of MuRF1 and reduced expression of MHC-I in tissue cross-section of the GA muscle in 
CBS+Met mice compared to WT mice. The arrows indicate the respective expression 
levels of MuRF-1 (low) and MHC-1 (high) in the fiber content of the GA muscle 
(Bar=200μm). (B) Quantification of MHC-1 expression from IHC images is shown on the 
right and where mice number (n)=4. (C) Quantification of MuRF-1 expression from IHC 
images is shown on the right, and where mice number (n)=4. (D) Western blots data 
showing protein expression of MHC-1 and MuRF-1 in the muscle of CBS+Met mice 
compared to WT mice. (E) Densitometric measurement of MHC-I and MuRF-1 from 
above Western blots images is shown on the right, and where mice number (n)=4. The 
overall difference between the experimental groups was determined by one-way or two-
way ANOVA, and a Tukey's post hoc analysis was run when overall statistically 
significant difference occurred in group means. Data are shown as means.e.m. and 
*p<0.05 vs. WT and #p<0.05 vs. CBS+Met. 
 
Discussion 
Skeletal muscle is the largest organ in the human body and makes up almost 
40% of the body’s weight (351). Muscle atrophy can occur due to result in the reduction 
of muscle mass, structural, and metabolic alteration of intrinsic muscle cells (138). 
Although HHcy was reported to cause muscle atrophy, the precise molecular 
mechanism of this effect was not identified before. In this study, I observed a reduction 
of body weights in HHcy mice (genetically engineered heterozygous CBS deficient mice) 
compared to age matched WT mice (Fig. 18E). As I also noticed their tibia lengths were 
similar with WT mice and muscle masses in hindlimb were lower in comparison to WT 
mice (Fig. 18C), suggesting that overall reduction of body weight may be at least partly 
due to the reduction of muscle mass (351). The muscle fiber is bound to connective 
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tissues, nervous tissues and blood vessels for oxygen and nutrient supply (366,367), so 
reduction of muscle mass may impair its functional capabilities. Indeed, I noticed that 
CBS mice have significantly poor performance in swimming and grip strength test 
compared to WT mice (Fig. 19). Interestingly, I also identified that NaHS administration 
could successfully mitigate these effects. The basic unit of the muscle is the muscle 
fiber, so any structural or morphological changes in muscle fiber can play havoc with it 
functional capabilities (368). Muscle atrophy is most often associated with fibrosis in 
muscle fibers, excessive accumulation of extracellular matrix (ECM) components, 
particularly collagen (369). This study showed that HHcy could actually significantly 
reduce CSAs, and induce fibrosis and collagen deposition in muscle fibers of CBS mice 
compared to WT mice and these effects of HHcy were improved upon NaHS 
administration (Fig. 20 and 21). This study is similar to previous study by Kanwar et al. 
[1976] found that HHcy can cause focal fragmentation, disruption and smearing of the Z‐
discs, increased collagen deposition in the besal lamina and disorganization of the 
myofilaments in the skeletal muscles (14) 
To further characterize underlying molecular changes of HHcy-mediated muscle 
atrophy, I analyzed intracellular localization of p-FOXO1 and FOXO1 by ICC experiment. 
Regulation of the subcellular localization of FOXO1 is critical to its transcriptional activity 
(354-356). My findings provide a new insight into the molecular background of the effect 
of HHcy in induced nuclear translocation of p-FOXO1. I observed induction of p-FOXO1 
expression and its nuclear localization upon treatment with Hcy and mitigated upon 
NaHS treatment (Fig. 22) led us to conclude that possibly Hcy stabilizes FOXO1 in the 
nucleus and thus allows it to carry on its transcriptional activity. Recent studies indicate 
that JNK is responsible for FOXO activation under stress conditions (357,358). As I also 
found high Hcy can activate JNK (chapter IV, Fig. 12), suggesting that JNK may also 
play a role in regulating nuclear stabilization of FOXO1.  When FOXO1 is 
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phosphorylated through Akt on S256, it creates a 14-3-3 binding site (370), that masks the 
nuclear localization signal (NLS) and prevents nuclear translocation, thereby inhibiting 
the activities of FOXO1 (371-373). However, during HHcy condition, Akt is 
downregulated, hence in addition to JNK pathway, reduced Akt-phosphorylation in 
C2C12 cells after Hcy treatment can stabilize FOXO1 inside the nucleus thus allowing 
them to carry their transcriptional activity (374,375).  
 Previous results suggested the role of FOXO1 transcription factors in the 
regulation of E3-ubiquitin ligases like Atrogin-1, and MuRF1 (376-379). Similarly, my 
findings suggested that expression of both MuRF1 and Atrogin-1 were upregulated in 
both in-vitro and in-vivo models and NaHS administration mitigated these effects. 
Together these results suggest that upregulation of these E3 ubiquitin ligases may be 
mediated through the FOXO1 transcription factors, which were found to be involved in 
most forms of atrophy (377,380-384). The overall results from this study demonstrate 
that HHcy-mediated oxidative/ER-stress upregulates MuRF1 and Atrogin-1 expression 
through JNK-dependent FOXO1 activation, which may degrade some vital proteins in 
muscle, such as MHC-I and MyoD (385,386). Indeed, I noticed that expression of MHC-I 
was decreased in skeletal muscle of CBS+Met mice (Fig. 24), which indicates that 
higher expression of MuRF-1 could trigger muscle atrophy via proteasomal degradation 
of its target proteins such as MHC-I (387).  
In conclusion, I have elucidated a well-defined signaling pathway for the upregulation of 
E3 ubiquitin ligases in HHcy-mediated skeletal muscle atrophy through activation of 
FOXO1 via JNK phosphorylation. I have also provided important data regarding potential 
mechanistic role H2S in mitigation of HHcy-mediated skeletal muscle atrophy. This study 
indicates that H2S could be developed as a potential therapeutic target in various forms 
of musclulopathies wherein HHcy is linked with metabolic dysfunction.
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CHAPTER VI 
SUMMARY 
HHcy is a well-accepted risk factor for vascular diseases (136), and several 
studies reported that HHcy conditions lead to skeletal muscle weakness and functional 
impairment (14,19,20). Results from the present study demonstrate that HHcy due to 
CBS+/- deficiency displays decreased bodyweight, angiogenesis and skeletal muscle 
mass, which ultimately lead to muscle myopathy. This is similar to neurological disorders 
such as amyotrophic lateral sclerosis (ALS), and multiple sclerosis, causing muscle 
degeneration and are also associated with HHcy (15). My dissertation elucidates the 
potential molecular mechanisms as to how HHcy mediates skeletal muscle myopathy via 
induction of oxidative and ER-stress responses, apoptosis, atrophy and reduction of 
angiogenesis (Fig. 25). This study also identified the apparent beneficial effects of H2S 
on mitigation of HHcy effects on skeletal muscle dysfunction.  
In chapter IV, I explored that high Hcy can induce intracellular oxidative and ER-
stress responses in skeletal muscle. Interestingly, I found that these cellular stress 
responses were successfully mitigated via NaHS intervention. Moreover, I found that 
HHcy induced JNK phosphorylation in both in-vitro and in-vivo models, however, I did 
notice that NaHS could not mitigate JNK-phosphorylation in the in-vitro model, but it 
could reduce JNK-phosphorylation in the in-vivo model. To my best knowledge, the 
possible explanation for this observed difference is in the in-vitro settings, I only studied 
a single readout (24 h post-HHcy), unlike the in-vivo CBS+/- model wherein I was able to
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observe the continuous or prolonged effect of the NaHS mediated phospho-JNK status. 
Previous studies have revealed that JNK-phosphorylation was able to activate c-Jun 
which further regulated the expression of several pro-inflammatory and proapoptotic 
genes (283-291). Indeed, my data showed that the apoptosis rate was induced after Hcy 
treatment in C2C12 cells and it was mitigated by the NaHS supplementation. 
Furthermore, I found inflammatory cytokines IL-6 and TNF-α were higher in plasma from 
CBS+/- as compared to wild-type mice; however, this effect was not mitigated via NaHS 
administration. The overall results from this chapter established the molecular 
mechanisms of the pathophysiological effects of HHcy in skeletal muscle myopathy via 
inducing cellular stress responses.  
In chapter V, I elucidated that HHcy can inhibit angiogenesis via PPARVEGF 
axis in a hindlimb ischemia model. This study showed that HHcy reduced the HIF1, 
VEGF and p-eNOS levels in skeletal muscle after 21 days of chronic ischemia 
(generated via femoral artery ligation; FAL) in CBS+/- mice compared to WT mice. 
Additionally, I also noticed that plasma nitrite levels were low in CBS+/- mice in 
comparison to WT mice after 21 days of ischemia, suggesting that HHcy may reduce the 
bioavailability of NO during angiogenesis in CBS+/- mice compared to WT mice. 
Interestingly, I also observed GYY4137 (another donor of H2S) supplementation 
mitigates this HHcy effect in CBS+/- mice. Furthermore, I identified the collateral vessel 
densities, and blood flow rates were lower in the hindlimb of CBS+/- mice after 21 days of 
ischemia compared to WT mice, and these effects were also attenuated via GYY4137 
treatment, suggesting that exogenous supplementation of GYY4137 can improve HHcy-
mediated angiogenic defects.  PPAR-γ is known to regulate angiogenesis via 
upregulation of VEGF levels (315), and VEGF can further activate eNOS during 
angiogenesis (320). Similar to the previous work this study showed that H2S could 
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induce PPAR-γ expression (323), which suggest that H2S may improve angiogenesis 
during chronic HHcy condition via PPAR-γ/VEGF axis.  
In chapter VI, I demonstrated the beneficial effect of H2S in the mitigation of 
HHcy-mediated skeletal muscle atrophy via JNK/FOXO axis. I found a reduction of body 
weights in CBS+/- mice compared to age-matched WT mice and since their tibia lengths 
were similar, thus this effect may partly be due to the reduction of muscle mass. Then, to 
study whether this reduction of muscle mass can impair muscle function, I did whole 
animal muscle fatigability tests (by swim performance and grip strength test). The 
findings showed that HHcy induced muscle fatigability in CBS+/- mice compared to WT 
mice and it was noticed that NaHS supplementation for 8 weeks was able to improve 
this effect. I also demonstrated that HHcy induced fibrosis, collagen deposition and 
reduced CSAs of skeletal muscle fibers in the gastrocnemius muscle of CBS+/- mice 
compared to WT mice; interestingly NaHS supplementation improved this condition. I 
elucidated that actually HHcy induced muscle atrophy through upregulation of MuRF-1 
and Atrogin-1 expressions via JNK/FOXO1 axis. Previous studies showed that Akt 
inhibits FOXO1 activity via preventing its nuclear localization, whereas JNK increases 
FOXO1 activity by promoting its import into the nucleus (352,356-359). This study 
showed that Akt-phosphorylation was attenuated, and JNK-phosphorylation was induced 
after Hcy treatment in C2C12 cells compared to vehicle controls, which possibly 
stabilizes FOXO1 in the nucleus and allows it to promote the expression of Atrogin-1 and 
MuRF-1 (E3 ubiquitin ligases). Whereas the upregulation of MuRF1 and Atrogin-1 due to 
HHcy condition may degrade their target proteins in the muscle fibers as reported 
previously for being responsible for muscle atrophy (361). Indeed, in this study, I noticed 
that upregulation of MuRF-1 degraded MHC-1 in CBS+/- mice compared to WT mice and 
this effect was substantially mitigated via NaHS treatment for 8 weeks.  
The overall results from this study demonstrated that HHcy can cause skeletal 
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muscle myopathy via cellular stress responses, apoptosis, inflammation, atrophy, and 
poor angiogenesis and identified a novel mechanism as to how H2S could mitigate these 
effects.  
 
Figure 25. Proposed model. Based upon the above findings, I have proposed a model 
that I firmly believe to be involved in HHcy-mediated skeletal muscle dysfunction.  
 
However, there is still a lot more left to clarify in this regard, such as (i) people 
develop HHcy due to many reasons; mutation of the CBS+/- gene is one of them. I 
studied the effects of HHcy on skeletal muscle using CBS+/- mouse model that is similar 
to the physiological conditions but not identical as observed in HHcy patients, so a 
suitable animal model is still lacking. The half-life of NaHS is short, therefore most of the 
effects of H2S vary in different studies. Moreover, delivery methods of H2S donors 
(NaHS, Na2S, GYY4137, etc.) are also a crucial factor because of changes in the 
pharmacokinetics and pharmacodynamics of these compounds. Also, there is a lot of 
hurdles to overcome with regard to identifying a proper delivery method for H2S. Skeletal 
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muscle dysfunction ranges from general muscle weakness and soreness to severe 
myopathy, muscle wasting and cachexia. Some of the complex dysfunctions do not 
necessarily originate from skeletal muscle and there are many variables and signaling 
pathways that need to be determined for devising the strategies to alleviate these 
pathological effects of HHcy on skeletal muscle myopathy. Although many studies have 
been devoted to clarifying the molecular mechanisms involved in E‐C coupling 
(excitation-contraction coupling) during skeletal muscle atrophy this was not assessed in 
my study due to limited resources and complexity associated with testing under in-vivo 
settings. I analyzed the FOXO1A localization via ICC experiment, however, I didn’t 
confirm my findings via western blot analysis using fractioned samples (nuclear and 
cytoplasmic extracts); (vi) Finally, from this study it is not still confirmed whether H2S is 
working via oxidative stress mechanisms or something else and whether other 
antioxidants (like N-acetylcysteine) has similar effects like H2S. So, future work should 
address these questions to devise potential therapeutic options. 
In brief, this work provides evidence that H2S is beneficial towards mitigating the 
HHcy-mediated skeletal injuries incited by oxidative/ER-stress responses. The findings 
from my study suggest that HHcy can inhibit angiogenesis via antagonizing the 
angiogenic signal pathways encompassing the PPAR-/VEGF axis, and H2S might be 
employed as a potential therapeutic option to alleviate the harmful metabolic effects of 
HHcy conditions. The findings from this study have been summarized in Fig. 23 
highlighting the sequential events during HHcy and its effects on skeletal muscle 
atrophy. 
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FUTURE DIRECTIONS 
 
HHcy-mediated skeletal muscle dysfunction involves a great number of 
cytokines, DNA methylation, metabolic alterations, hormonal regulation, etc. (7). The 
primary focus of this study was to determine how HHcy promotes skeletal muscle 
myopathy through induction of oxidative and ER-stress responses, apoptosis, atrophy, 
and impairment of angiogenesis, and to study whether or not H2S could mitigate the 
effects of HHcy during skeletal muscle myopathy. Although this study was able to 
demonstrate the above effects, there are many other factors and signaling pathways that 
need to be determined to devise any effective and potential treatment to improve these 
detrimental effects of HHcy in skeletal muscle dysfunction. 
As I showed that NaHS improved skeletal muscle functions via mitigation of 
cellular stress responses using CBS+/- mouse model. However, people develop HHcy 
due to various other reasons. The western diet contains high levels of methionine (such 
as in red meat), and studies showed that an excessive intake of the high methionine diet 
could elevate Hcy levels (79,246). So, to elaborate further, I wish to study and extend my 
hypothesis to in a diet-induced HHcy model. 
As ER is considered as a storehouse of Ca2+ and alterations of Ca2+ release from 
ER contributes to dysregulation of muscle's contractility.  In this study, I found HHcy 
mediated ER-stress in muscle, however, the effects of HHcy on sarcoplasmic reticulum's 
Ca2+ handling and whether that has any role in skeletal muscle fatigability remains 
unresolved. In the future, I want to study the effects of HHcy on E-C coupling, Ca2+  
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release, ATP/ADP ratios, mitochondrial biogenesis in the skeletal muscle. 
It has been known that aging is associated with a decline in skeletal muscle 
mass and strength and a slowing of muscle contraction impact the quality of life for the 
older people. Previous studies demonstrated that older people have significantly higher 
levels of Hcy compared to younger ones (387,388). It is also reported that HHcy can 
significantly lower physical functions in older people compared to age-matched healthy 
subjects (138), which suggests that aging is one of the potential risk factors to be 
considered in this process (139). In the future, I also want to study the role of Hcy in 
decline in physical function during the aging process.  
Loss of skeletal muscle mass (i.e., muscle wasting) is a major component of 
cachexia; in particular, malnutrition is considered a critical factor (389,390). Whereas 
plasma total Hcy levels are dependent on nutritional status (391), deficiency of folic acid 
and vitamins B6, B12 and B9 are also the causal factors for the induction of HHcy (391). 
Since the effect of Hcy for causation of cachexia is not studied. So, in the future, I want 
to examine my hypothesis in light of muscle cachexia.
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LIST OF ABBREVIATIONS AND SYMBOLS 
 
 
HHcy:     Hyperhomocysteinemia 
CBS:     Cystathionine--synthase 
CSE:     Cystathionine γ-lyase 
WT:     Wild-type 
Met:     Methionine 
NaHS:    Sodium hydrogen sulfide 
UPR:     Unfolded protein response 
IRE1α:    Inositol-requiring enzyme-1α 
XBP-1:    X-box binding protein-1 
PERK:    PRKR-like ER kinase 
ATF6:     Activating transcription factor-6 
TRAF2:    TNF receptor-associated factor-2 
JNK:     C-Jun N-terminal kinase 
ASK1:     Apoptosis signal-regulating kinase-1 
FOXO:    Forkhead box protein O 
MuRF1:    Muscle RING-finger protein-1 
MAFBx:    Muscle atrophy F-box 
MDA:     Malondialdehyde 
ROS:     Reactive oxygen species 
ER:     Endoplasmic reticulum 
DCFDA:    2', 7’–dichlorofluorescin diacetate 
ELISA:    Enzyme-linked immunosorbent assay 
MHC-I:    Myosin heavy chain isoform (MHC)-I 
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H2S:     Hydrogen sulfide 
FAL:     Femoral artery ligation 
HIF1α:    Hypoxia-Inducible Factor 1 α 
PPAR-γ:    Peroxisome proliferator-activated receptor-γ 
VEGF:    Vascular endothelial growth factor 
eNOS:    Endothelial nitric oxide synthase 
EC:     Endothelial cell 
DNMT:    DNA methyltransferase 
MS:     Methionine synthase 
SAH:     S-adenosyl Hcy 
THF:     Tetrahydrofolate 
GPx:     Glutathione peroxidase 
SOD:    Superoxide dismutase 

















Table 4. Physiological parameters of experimental mice. 
Parameters 
(mean+/-s.e.m) 
WT CBS+Met CBS+Met+NaHS WT+NaHS 
BW 0 weeks (gm) 23.614+0.7566 20.16045+0.4921 20.70098+0.7799 24.13964+0.5933 
BW 4 weeks (gm) 27.125+0.6500 22.563+0.6325 24.568+0.6852 28.214+0.7481 
BW 8 weeks (gm) 29.03981+0.4557 23.15864+0.7504 26.45705+0.5716 30.54376+0.6692 
Tibia length (mm) 15.36+1.2923 14.98+1.1214 14.59+1.1241 15.45+1.2832 
Gastroc (gm) 0.14+0.0094 0.1+0.0098 0.121+0.0094 0.142+0.0064 
Quad (gm) 0.189+0.0111 0.155+0.0111 0.162+0.0111 0.191+0.0111 
TA (gm) 0.053+0.0116 0.049+0.0094 0.05+0.0116 0.054+0.0116 
EDL (gm) 0.019+0.0013 0.017+0.0018 0.017+0.0013 0.02+0.0013 
Soleus (gm) 0.013+0.0053 0.009+0.0004 0.01+0.0054 0.006+0.0054 
Note: BW: Body weight 
 
Table 5: Results from exercise capacity test.  
Distance traveled in swimming test (m) 
Srl# WT CBS+Met CBS+Met+NaHS WT+NaHS 
1 26.28 12.36 18.33 25.36 
2 20.53 9.63 23.34 28.45 
3 30.54 17.33 19.34 19.52 
4 31.33 13.33 16.33 31.03 
5 29.36 18.35 22.33 29.37 
6 20.37 10.35 15.36 24.32 
7 27.33 13.03 29.65 26.35 
8 23.21 15.33 24.33 24.99 
9 19.85 20.64 18.63 22.75 
Mean+/-s.e.m. 25.4216+/-1.5198 14.4820+/-1.2372 20.8475+/-1.5003 25.7928+/-1.1734 
Time spent in swimming test (mins) 
 WT CBS+Met CBS+Met+NaHS WT+NaHS 
1 23.15 15.55 16.67 23.67 
2 17.52 14.10 21.79 27.17 
3 29.02 16.69 15.00 19.16 
4 22.53 13.63 17.65 28.37 
5 22.63 17.32 18.36 22.37 
6 25.36 18.36 22.30 24.30 












8 28.63 19.33 25.65 26.33 
9 22.37 12.75 27.52 23.20 
Mean+/-s.e.m. 23.90+/-1.1657 15.86+/-0.74266 21.03+/-1.44570 24.80+/-1.03671 
Latency to fall in Rolla rod grip test (Secs) 
 WT CBS+Met CBS+Met+NaHS WT+NaHS 
1 253 153 200 251 
2 263 163 210 249 
3 230 186 199 246 
4 198 210 176 198 
5 200 146 230 202 
6 263 163 156 193 
7 257 155 277 245 
8 243 187 244 168 
9 271 139 261 253 
Mean+/-s.e.m. 242.36+/-9.08560 167.21+/-7.65148 217.27+/-13.1677 223.14+/-10.7941 
Bioseb Grip strength test-strength/BW (g-force/gm) 
 WT CBS+Met CBS+Met+NaHS WT+NaHS 
1 35.10 15.15 23.10 40.42 
2 30.02 10.15 35.12 46.15 
3 40.12 21.12 31.45 30.13 
4 35.36 13.85 21.14 36.45 
5 39.37 25.36 30.30 40.52 
6 44.35 35.63 40.37 39.33 
7 36.33 19.87 33.36 33.33 
8 31.79 24.63 37.32 28.33 
9 29.32 22.32 43.33 43.27 
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Abstract
Higher levels of nonprotein amino acid homocysteine (Hcy), that is,
hyperhomocysteinemia (HHcy) (~5%of general population) hasbeen associated
with severe vasculopathies in different organs; however, precise molecular
mechanism(s) as to how HHcy plays havoc with body’s vascular networks are
largely unknown. Interventional modalities have not proven beneficial to
counter multifactorial HHcy’s effects on the vascular system. An ancient Indian
form of exercise called ‘yoga’ causes transient ischemia as a result of various
body postures however the cellular mechanisms are not clear. We discuss a
novel perspective wherein we argue that application of remote ischemic
conditioning (RIC) could, in fact, deliver anticipated results to patients who are
suffering from chronic vascular dysfunction due to HHcy. RIC is the
mechanistic phenomenon whereby brief episodes of ischemia‐reperfusion
events are applied to distant tissues/organs; that could potentially offer a
powerful tool in mitigating chronic lethal ischemia in target organs during
HHcy condition via simultaneous reduction of inflammation, oxidative and
endoplasmic reticulum stress, extracellular matrix remodeling, fibrosis, and
angiogenesis. We opine that during ischemic conditioning our organs cross talk
by releasing cellular messengers in the form of exosomes containing messenger
RNAs, circular RNAs, anti-pyroptotic factors, protective cytokines like musclin,
transcription factors, small molecules, anti‐inflammatory, antiapoptotic factors,
antioxidants, and vasoactive gases. All these could help mobilize the bone
marrow–derived stem cells (having tissue healing properties) to target organs.
In that context, we argue that RIC could certainly play a savior ’s role in an
unfortunate ischemic or adverse event in people who have higher levels of the
circulating Hcy in their systems.
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ABSTRACT
In the United States, breast cancer is the second leading cause of death among 
women, and even though different therapies can treat primary breast tumors, most 
breast cancer-related deaths (> 95% ) occur due to m etastasis. A  m ajority (~70% ) 
of breast tum ors are found to express estrogen receptor, and a significant portion 
(~ 90% ) of ER-positive (ER +) breast tum ors are also androgen receptor-positive 
(AR +). A lthough ER is know n to prom ote tum origenesis, the role and underlying 
mechanism(s) of AR in these closely knit processes remain controversial. Endocrine 
therapies are the m ost com m only used treatm ent for patients w ith ER +  breast 
tumors; but, ~30%-50% of initially responsive patients develop resistance to these 
therapies. W hereas 70% –90%  of all breast tum ors are AR + and AR overexpression is 
correlated w ith endocrine resistance, but the precise m olecular m echanism (s) for this 
association is yet to be studied. M ultip le  m echanism s have been proposed to show  AR 
and ER  interactions, w hich  indicate that AR  m ay preferentially  regulate expression  of 
a subset of ER-responsive genes and that may be responsible for breast cancer and 
its progression in  affected patients. O n the other hand, m ost of the ER + breast tum ors 
fo u n d  in  p o s t -m e n o p a u s a l w o m e n  ( ~ 8 0 % ) ;  a n d  th e y  h a v e  v e ry  lo w  1 7 β -e s tra d io l a n d  
high androgen levels, but how  these horm onal changes m ake som eone m ore prone 
to  cancer phenotype has long been a  d isputed issue. In  this study, w e have discussed 
m ultip le m olecular m echanism s that w e believe are central to  the understanding of 
the overall contributions of AR in breast cancer and its m etastasis in post-m enopausal 
women.
INTRODUCTION
In the United States, breast cancer is the second 
leading cause of death among women (40,610 deaths 
and 252,710 new cancer cases are estimated in 2017) 
[1]. There are different therapies (surgery, radiotherapy, 
chemotherapy, endocrine therapies, or combination of 
these therapies) available which can treat primary tumor; 
however, most breast cancer-related deaths occur due 
to distance organ metastasis (mainly lung, brain and 
liver). Whereas, most epidemiological studies showed 
inconsistent finding in a correlation between serum 
androgen levels and breast cancer risk; but whether this 
association is consistent in post-menopausal women with 
breast cancers (who have high androgens levels and low 
17β-estradiol) is not understood [2–11]. Previous studies 
have implicated a possible role for AR in breast cancers 
[12–14], and AR is found to be predominantly expressed 
in in-situ, invasive and metastatic breast cancers (~90% 
of primary tumors and 75% of metastases) [15–18]; 
however, the precise molecular mechanism(s) for AR's 
contribution to breast cancer is largely unknown. Hence, a 
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in Type 2 Diabetic Subjects from Gujarati population-India; Molecular Cytogenetics 2014, 
7(Suppl 1): P36 
15. Shah A, Sheth F, Majumder A, et al. Effect of PPAR-γ2 gene Pro12Ala and ADR-β3 gene 
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Trp64AArg polymorphism on glucose homeostasis in Type 2 diabetic subjects from Gujarat-
India; Molecular Cytogenetics 2014, 7(Suppl 1): P101 
16. Majumder A, Sheth J, Sheth F, et al. Effect of PPAR- γ2 gene polymorphism (Pro12Ala) on 
HbA1C and its association with BMI in Type 2 diabetes subjects from Western India; Endocr 
Rev 2013; Vol. 34  
 
List of papers under way: 
1. Laha A, Majumder A, Singh M, et al. Regulation of Forkhead Box class O and Cell Death in 
Skeletal Muscle by Hydrogen Sulfide treatment during Hyperhomocysteinemia. Can J 
Physiol Pharmacol. 2018; MS-ID: cjpp-2018-0496. [under review] 
2. George AK, Homme RP, Majumder A, et al. Hydrogen sulfide intervention in cystathionine-β-
synthase mutant mouse helps restore ocular homeostasis. Int J Ophthalmol 2018; MS ID: 
IJO-2018-0569. [under review] 
3. Homme RP, Laha A, Majumder A, et al. Modulation of Inflammatory Pathway via inhibition 
of Nuclear Factor-Kappa Beta to Mitigate Vasculopathy in Diabetic Retinopathy. Int J 
Ophthalmol 2018; MS ID: IJO-2018-8814. [under review] 
4. Master K, Majumder A, George AK, et al. Circular RNAs as the master genome regulators in 
the eye genome. Molecular Vision. [will be submitted soon] 
5. George AK, Majumder A. Homme RP, et al. Genetics of Hyperhomocystenemia and ocular 
diseases. Ophthalmic Genetics. [will be submitted soon] 
 
Travel grant recommended: 
1. AHA predoctoral fellowship 2018 [submitted] 
2. ASBMB travel award $1000 for Annual Meeting of Experimental Biology 2018 (from ASBMB) 
held at San Diego, CA. 
3. Early career forum travel grant, 2013: (from Endocrine Society, USA) $400 & complementary 
registration fees. 
4. Department of Biotechnology; Ministry of Science and Technology, 2013: full travel award for 
attending ENDO 2013: The 95th Annual Meeting & Expo. held at San Francisco, CA. 
 




1. Evaluation of hydrogen sulfide (H2S) effects on visual functions and pyroptosis in a mouse 
model of hyperhomocysteinemia. ARVO Annual Meeting Abstract Honolulu, Hawaii, April 
29 - May 3, 2018: 
2. Hyperhomocysteinemia-Mediated Endoplasmic Reticulum Stress in Skeletal Muscle 
Dysfunction via JNK/pro-inflammatory Pathway, FASEB Journal, Vol. 32, No. 1_supplement 
April 2018, Annual meeting of Experimental Biology-2018, San Diego, CA. 
3. Hydrogen Sulfide Improves Hyperhomocysteinemia-Mediated Impairment of Angiogenesis in 
Skeletal Muscle; FASEB Journal, Vol. 32, No. 1_supplement, April 2018, Annual meeting of 
Experimental Biology-2018, San Diego, CA. 
4. Ciglitazone Prevent Inflammation in Skeletal Muscle Induced by Hyperhomocysteinemia; 
FASEB Journal, Vol. 31, No. 1_supplement April 2017; Annual meeting of Experimental 
Biology-2017, Chicago, IL. 
5. Role of Hydrogen Sulfide (H2S) on Homocysteine Mediated Glutamate Excitotoxicity, 
Endoplasmic Reticulum Stress and Pyroptosis in Retina; FASEB Journal, Vol. 32, No. 
1_supplement April 2018, Annual meeting of Experimental Biology-2018, San Diego, CA. 
6. Effect of PPAR-γ2 gene Pro12Ala polymorphism (rs1801282), vitamin D3 and BMI in type 2 
diabetic subjects; its association with hemoglobin A1c level: a study on 902 subjects from 
Western India; ENDO 2014: The 96th Annual Meeting & Expo. International conference to be 
held at Chicago, IL. 
7. Effect of PPAR2 gene polymorphism (Pro12Ala) on HbA1C and its association with BMI in 
Type 2 diabetes subjects from Western India; ENDO 2013: The 95th Annual Meeting & 
Expo. International conference held at San Francisco, CA from June 14-18, 2013. 
8. Recommended for Young Scientist Award for present full paper entitled “Effect of PPAR-γ2 
Gene Pro12Ala Polymorphism (Rs1801282) and Vitamin D3 on Glucose Homeostasis in Type 
2 Diabetic Subjects from Gujarat-India” 39th Annual Meeting of the Indian Society of 
Human Genetics; International seminar held at the Ahmedabad, India, from 22nd - 25th 
January 2014. 
9. Antenatal screening of HbF levels show gender-biasness in haemoglobin disorders (HbE β, β):  
A study in age-matched patients in Eastern Indian Population” International seminar on 10th 
Annual Conference of Indian Society for Prenatal Diagnosis & Therapy held at Mumbai, 
India.   
 
PREVIOUS RESEARCH EXPERIANCES: 
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Last Employed:  Research Fellow at Institute of Human Genetics, Genetic Centre, India (2nd April 
2012 to 31st March 2014) 
Project Title: “Effect of genetic variations in PPARγ-2 and ADRβ-3 gene in type 2 diabetic subjects 
of Gujarat, in relation to drug response”; Funding agency: Gujarat Institute of Chemical 
Technology (GICT). Institution: Foundation for Research in Human Genetics and Endocrinology, 
Institute of Human Genetics. Guide: Jayesh J Sheth, Ph.D., Director, Institute of Human Genetics 
(MS University affiliated) 
 
1) From 2nd November 2011 to 28th March, 2012: 
Project Title: “A Polymorphism in the Gene for IGF-1 and its Functional Properties and Risk for 
Type 2 Diabetes and Myocardial Infarction” 
Institution: Molecular biology Dept, Galaxy Concepts Private Limited (ISO 9001-2008 certified), 
Kolkata, India. Guide: Dr. Prianka Pusp Research associate and faculty in Galaxy Concepts Private 
Limited. 
Brief Description: There are many evidences that low levels of IGF-1 play a role in the 
pathogenesis of type 2 diabetes and cardiovascular diseases. I studied the role of a genetic 
polymorphism in the promoter region of the IGF-1 gene and measured anthropometric indices and 
other biochemical parameters along with genotyping. Conclusion: My study suggests that a 
genetically determined exposure to relatively low IFG-1 levels is associated with an increased risk 
for type 2 diabetes and myocardial infarction. 
 
2) From 1st October 2009 to 30th June, 2010: 
Project Title: “Study of IVS 1-5 GC mutation by ARMS-PCR method in Eβ-thalassaemia 
patients to determine genotype-phenotype correlation”. Institution: Institute of Genetic 
Engineering (Affiliated to WBUT), West Bengal, India. Guide: Dr. Sudipa Chakravarty, Vice 
Principal of Institute of Genetic Engineering.  
Brief Description: I studied Eβ-thalassaemia patients with age ranging from 11 months to 50years. 
Studied Hemoglobin parameters (HbF, HbA0, HbA2) by HPLC method and CBC parameters 
(MCV, MCH, MCHC, HCT etc.) by Automated Cell Counter and genetic analysis was performed 
by ARMS-PCR for IVS 15 GC. Conclusion: a) Patients having IVS 1-5 GC mutation are 
clinically less severe/ better i.e. most of these patients require either occasional or no blood 
transfusion. b) The Severity of the haemoglobinopathy disease process is related to genetically 




3) From 2nd October 2008 to 30th April, 2009: 
Project Title: “Phenotypic analysis of SNP variants of the alpha chain of Globin protein related to 
haemoglobinopathy”. Institution: Institute of Genetic Engineering (Affiliated to WBUT), West 
Bengal, India. Guide:  Dr. Amit Chakravarty, director of Institute of Genetic Engineering. 
Brief Description: The PDB file of deoxy-hemoglobin was collected from RCSB-PDB database. 
The studies of SNPs were done by inducing previously collected mutations in deoxy hemoglobin 
structure by using Swiss-PDB Viewer software. Then the energy of the mutated structures was 
minimized using GROWMACS and RMSD values were calculated using VMD. Finally, a graph 
was plotted against RMSD values vs. type mutations. Conclusion:  Non-polar to polar or polar to 
non-polar mutations are more severe than non-polar to non-polar or polar to polar mutations. 
 
Extra Qualifications (Certificates): 
• 3 months training in Assisted Reproductive Technology in human (IVF, ICSI, IUI). 
• Training in Biotechnology techniques and its application. 
• Workshop on Metabolic and Molecular Diagnosis- clinical & laboratory approach. 
• Certification Course in computer languages (C, C++) 
• Technical Expertise - O.S. Platforms: WIN; LINUX; Mac; Scripting languages: HTML; M.S. 
office and other Software’s.  
 
Seminars / Conference attained (Award & Certificates): 
• Annual meeting of Experimental Biology-2018, San Diego, CA, USA. 
• Annual meeting of Experimental Biology-2017, Chicago, IL, USA. 
• The 95th Annual Meeting & Expo Endocrine Society 2013, San Francisco, CA, USA.  
• National Symposium on 10th Annual Conference of “Indian Society for Prenatal Diagnosis & 
Therapy” in Mumbai, India.  
• Diabetes & its Complications: Search for Prevention & Cure, National Seminar, Ahmedabad, 
India.  
• Award & Certificate for Best Project presentation on Post Genome impact from “1st Annual 
DNA Day contest” in Institute of Genetic Engineering (WBUT), West Bengal, India. 
• 4th World Congress on “Mild Approaches in Assisted Reproduction” arranged by International 
Society for Mild Approaches in Assisted Reproduction (ISMAAR), Kolkata, India.  
